header logo image


Page 791«..1020..790791792793..800810..»

Blue Origin Launches Its First Space Tourism Rocket In Seven Months – And Hopes To Take Humans To Space In 2020 – Forbes

December 15th, 2019 7:46 am

This was the company's first launch since May

Jeff Bezos company Blue Origin has successfully launched its New Shepard vehicle for a 12th time, as it continues its efforts to begin launching humans on short jaunts into space.

Today at 12.46 P.M. Eastern Time, the U.S. companys 18-meter tall rocket launched from the companys test site in West Texas on the NS-12 mission. On board was a capsule, designed to one day carry up to six people, but on this occasion outfitted with a variety of experiments and sensors.

After reaching a maximum altitude of 104.5 kilometers, the rocket booster separated from the capsule and the two descended back towards Earth. The booster fired up its engines again and performed a controlled landing back on the ground, while the capsule descended safely and slowly to Earth via parachute. The whole flight lasted about ten minutes.

Congratulations to our New Shepard team, said Ariane Cornell, Director of Astronaut and Orbital Sales for Blue Origin, in a live stream for the launch. Look at that capsule. Man I wish I'd been on board today!

This was the sixth flight for this particular New Shepard vehicle, eclipsing the record of five flights made by its predecessor. This particular rocket has been an operational payload vehicle for several flights, meaning there are no more updates to the system, Blue Origin said in a pre-launch statement.

The booster touched down about seven minutes after launching,

New Shepard is designed to be a space tourism vehicle, taking paying customers on short trips into space lasting several minutes and giving them a brief stint of weightlessness before returning to Earth. Tickets are estimated to cost in the region of $200,000.

Blue Origin, which is also developing an orbital rocket called New Glenn, had hoped to start launching its first humans to space in 2019. However, delays have meant that is now almost certain to be pushed back to at least 2020. The company's last launch came in May 2019, while it has kept most of its plans for these inaugural human flights under wraps for now.

Were never going to fly until were absolutely ready, Blue Origins CEO Bob Smith told CNBC last month. [We] have to go look at all the analysis, and then convince ourselves that were ready to go So it probably will be next year.

On todays flight, however, were a number of commercial payloads, with Blue Origin noting it had now launched payloads for 100 customers. These included a NASA recycling experiment, a space plant experiment, and two art experiments in partnership with the band OK Go.

One of our educational payloads from Columbia University, designed and built by undergraduate students and advised by [astronaut] Dr. Michael Massimino, will study the acute impacts of microgravity environments on cell biology, Blue Origin noted in a pre-launch update. This is crucial for humans living and working in space.

Blue Origin also noted that thousands of postcards written by children were on board the flight, from their non-profit organisation Club for the Future. The Club's mission is to inspire future generations to pursue careers in STEM and help visualize the future of life in space, the company said.

Now Blue Origin will be hoping it can move ever closer to human flights. While no updated timescale for that has yet been released for when those might occur, todays launch and landing is at least another step in that direction.

We've got a couple more flights before we're going to get there, said Cornell.

Read this article:
Blue Origin Launches Its First Space Tourism Rocket In Seven Months - And Hopes To Take Humans To Space In 2020 - Forbes

Read More...

Cell Separation Technology Market Overview, Growth Forecast, Demand and Development Research Report to 2027 – VaporBlash

December 15th, 2019 7:46 am

Transparency Market Research (TMR)has published a new report on the globalcell separation technology marketfor the forecast period of 20192027. According to the report, the global cell separation technology market was valued at ~US$ 5 Bnin 2018, and is projected to expand at a double-digit CAGR during the forecast period.

Overview

Cell separation, also known as cell sorting or cell isolation, is the process of removing cells from biological samples such as tissue or whole blood. Cell separation is a powerful technology that assists biological research. Rising incidences of chronic illnesses across the globe are likely to boost the development of regenerative medicines or tissue engineering, which further boosts the adoption of cell separation technologies researchers.

Expansion of the global cell separation technology market is attributed to an increase in technological advancements and surge in investments in research & development, such asstem cellresearch and cancer research. The rising geriatric population is another factor boosting the need for cell separation technologies Moreover, the geriatric population, globally, is more prone to long-term neurological and other chronic illnesses, which, in turn, is driving research to develop treatment for chronic illnesses. Furthermore, increase in the awareness about innovative technologies, such as microfluidics, fluorescent-activated cells sorting, and magnetic activated cells sorting is expected to propel the global cell separation technology market.

Want to know the obstructions to your companys growth in future? Request a PDF sample here

North America dominated the global cell separation technology market in 2018, and the trend is anticipated to continue during the forecast period. This is attributed to technological advancements in offering cell separation solutions, presence of key players, and increased initiatives governments for advancing the cell separation process. However, insufficient funding for the development of cell separation technologies is likely to hamper the global cell separation technology market during the forecast period. Asia Pacific is expected to be a highly lucrative market for cell separation technology during the forecast period, owing to improving healthcare infrastructure along with rising investments in research & development in the region.

Rising Incidences of Chronic Diseases, Worldwide, Boosting the Demand for Cell Therapy

Incidences of chronic diseases such as diabetes, obesity, arthritis, cardiac diseases, and cancer are increasing due to sedentary lifestyles, aging population, and increased alcohol consumption and cigarette smoking. According to the World Health Organization (WHO), 2020, the mortality rate from chronic diseases is expected to reach73%, and in developing counties,70%deaths are estimated to be caused chronic diseases. Southeast Asia, Eastern Mediterranean, and Africa are expected to be greatly affected chronic diseases. Thus, the increasing burden of chronic diseases around the world is fuelling the demand for cellular therapies to treat chronic diseases. This, in turn, is driving focus and investments on research to develop effective treatments. Thus, increase in cellular research activities is boosting the global cell separation technology market.

To Obtain All-Inclusive Information On Forecast Analysis Of Global Market, Request A PDF Brochure Here.

Increase in Geriatric Population Boosting the Demand for Surgeries

The geriatric population is likely to suffer from chronic diseases such as cancer and neurological disorders more than the younger population. Moreover, the geriatric population is increasing at a rapid pace as compared to that of the younger population. Increase in the geriatric population aged above 65 years is projected to drive the incidences of Alzheimers, dementia, cancer, and immune diseases, which, in turn, is anticipated to boost the need for corrective treatment of these disorders. This is estimated to further drive the demand for clinical trials and research that require cell separation products. These factors are likely to boost the global cell separation technology market.

According to the United Nations, the geriatric population aged above 60 is expected to double 2050 and triple 2100, an increase from962 millionin 2017 to2.1 billionin 2050 and3.1 billion2100.

Productive Partnerships in Microfluidics Likely to Boost the Cell Separation Technology Market

Technological advancements are prompting companies to innovate in microfluidics cell separation technology. Strategic partnerships and collaborations is an ongoing trend, which is boosting the innovation and development of microfluidics-based products. Governments and stakeholders look upon the potential in single cell separation technology and its analysis, which drives them to invest in the development ofmicrofluidics. Companies are striving to build a platform utilizing their expertise and experience to further offer enhanced solutions to end users.

Stem Cell Research to Account for a Prominent Share

Stem cell is a prominent cell therapy utilized in the development of regenerative medicine, which is employed in the replacement of tissues or organs, rather than treating them. Thus, stem cell accounted for a prominent share of the global market. The geriatric population is likely to increase at a rapid pace as compared to the adult population, 2030, which is likely to attract the use of stem cell therapy for treatment. Stem cells require considerably higher number of clinical trials, which is likely to drive the demand for cell separation technology, globally. Rising stem cell research is likely to attract government and private funding, which, in turn, is estimated to offer significant opportunity for stem cell therapies.

Biotechnology & Pharmaceuticals Companies to Dominate the Market

The number of biotechnology companies operating across the globe is rising, especially in developing countries. Pharmaceutical companies are likely to use cells separation techniques to develop drugs and continue contributing through innovation. Growing research in stem cell has prompted companies to own large separate units to boost the same. Thus, advancements in developing drugs and treatments, such as CAR-T through cell separation technologies, are likely to drive the segment.

As per research, 449 public biotech companies operate in the U.S., which is expected to boost the biotechnology & pharmaceutical companies segment. In developing countries such as China, China Food and Drug Administration(CFDA) reforms pave the way for innovation to further boost biotechnology & pharmaceutical companies in the country.

Global Cell Separation Technology Market: Prominent Regions

North America to Dominate Global Market, While Asia Pacific to Offer Significant Opportunity

In terms of region, the global cell separation technology market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America dominated the global market in 2018, followed Europe. North America accounted for a major share of the global cell separation technology market in 2018, owing to the development of cell separation advanced technologies, well-defined regulatory framework, and initiatives governments in the region to further encourage the research industry. The U.S. is a major investor in stem cell research, which accelerates the development of regenerative medicines for the treatment of various long-term illnesses.

The cell separation technology market in Asia Pacific is projected to expand at a high CAGR from 2019 to 2027. This can be attributed to an increase in healthcare expenditure and large patient population, especially in countries such as India and China. Rising medical tourism in the region and technological advancements are likely to drive the cell separation technology market in the region.

Launching Innovative Products, and Acquisitions & Collaborations Key Players Driving Global Cell Separation Technology Market

The global cell separation technology market is highly competitive in terms of number of players. Key players operating in the global cell separation technology market include Akadeum Life Sciences, STEMCELL Technologies, Inc., BD, Bio-Rad Laboratories, Inc., Miltenyi Biotech, 10X Genomics, Thermo Fisher Scientific, Inc., Zeiss, GE Healthcare Life Sciences, PerkinElmer, Inc., and QIAGEN.

These players have adopted various strategies such as expanding their product portfolios launching new cell separation kits and devices, and participation in acquisitions, establishing strong distribution networks. Companies are expanding their geographic presence in order sustain in the global cell separation technology market. For instance, in May 2019, Akadeum Life Sciences launched seven new microbubble-based products at a conference. In July 2017, BD received the U.S. FDAs clearance for its BD FACS Lyric flow cytometer system, which is used in the diagnosis of immunological disorders.

Excerpt from:
Cell Separation Technology Market Overview, Growth Forecast, Demand and Development Research Report to 2027 - VaporBlash

Read More...

Looney gives up two aspects of diet to combat neuropathy – NBCSports.com

December 15th, 2019 7:45 am

D'Angelo Russell is rapidly approaching a date some NBA observers have circled since the Warriors acquired him this summer.

Golden State can trade Russell as soon as Sunday, Dec. 15, and the 23-year-old has been the source of trade speculation during his time in the Bay Area. The Athletic's Jon Krawczynski reported Wednesday, citing sourcesthat the Minnesota Timberwolves "remain interested in Russell" and that the guard "seems to be realistic in understanding that he may not be long for the Warriors once Steph Curry and Klay Thompson return to full health."

Russell is averaging a career-high 22.4 points per game this season to go with 6.1 assists and 3.1 rebounds, serving as the top offensive option in the absence of his All-Star teammates. He knew he wouldn't play much with Thompson this season as he recovers from a torn ACL, but Curry's broken hand threw a wrench into the Warriors' -- and thus Russell's -- prospects this season. Warriors coach Steve Kerr praised how Russell has handled the rumors surrounding him.

"Money doesn't buy peace of mind," Kerr said Friday morning (H/T San Francisco Chronicle's Connor Letourneau)."It doesn't buy a sense of belonging, a sense of, 'Alright, this is my team.' If there's speculation that you're going to be traded all the time, I don't care how much money you make, I don't care who you are. That's tough. That's no fun to deal with, and this season has been nowhere close to what D'Angelo thought it would be when he first signed with us.

"There's no Steph. We're struggling to win games. He's had his own injuries, and we're throwing all kinds of different lineups out there based on the other injuries we've faced."

Russell has played in just 15 of the Warriors' 27 games this season, playing on a team that looksfar more like the Los Angeles Lakers of his first two seasons than the playoff-contending Brooklyn Nets a year ago -- let alone the reigning Western Conference champion Warriors.

[RELATED:How Warriors' Chriss earning chance to start at center]

Kerr, who entered this season with the highest winning percentage in NBA history (.785), is as aware of Golden State's dramatically different reality as anyone. He said it has only brought out the best in Russell.

"So given all that, he's played really well, and he's been a great teammate and he's doing everything he needs to do to solidify his position here," Kerr continued."But this is the NBA here, and we never know what's coming, what's happening. So, it's a difficult position to be in in general, but for him in particular it's strange set of circumstances and he's handling it really well."

Whether or not the Warriors trade Russell, it's clear Kerr holds him in high regard.

Excerpt from:

Looney gives up two aspects of diet to combat neuropathy - NBCSports.com

Read More...

Athenex Announces Superior Response and Survival with Lower Neuropathy of a Novel Oral Paclitaxel versus IV Paclitaxel in Treatment of Metastatic…

December 15th, 2019 7:45 am

First oral taxane to demonstrate superior response rate and overall survival compared to IV paclitaxel in a Phase III clinical trial

Data to be presented today in an oral presentation at the 2019 San Antonio Breast Cancer Symposium (SABCS)

BUFFALO, N.Y., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer, today announced results from a pivotal Phase III clinical trial showed oral paclitaxel and encequidar had superior response and survival with much lower incidence and severity of neuropathy compared to IV paclitaxel in the treatment of metastatic breast cancer. For additional details on the study results, please refer to the abstract GS6-01, which can be found online here.

Dr. Rudolf Kwan, Chief Medical Officer of Athenex, commented, Oral paclitaxel and encequidar is the first oral taxane to demonstrate in a Phase III study statistically significant improvement in response rate and median overall survival compared to IV paclitaxel, in the treatment of metastatic breast cancer while associated with a much lower incidence and severity of neuropathy. We believe these data suggest the potential for oral paclitaxel and encequidar to provide an important advance in the management of patients with metastatic breast cancer.

These results will be presented in an oral presentation today at the 2019 San Antonio Breast Cancer Symposium (SABCS) at 3:15 p.m. CT in General Session 6 in Hall 3 of the Henry B. Gonzalez Convention Center in San Antonio, Texas, and were selected for the official SABCS press program at 7:30 a.m. CT.

The Orascovery platform was initially developed by Hanmi Pharmaceuticals and licensed exclusively to Athenex for all major worldwide territories except Korea, which is retained by Hanmi.

About Athenex, Inc.

Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery, development, and commercialization of next-generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform, and a Global Supply Chain Platform. The Companys current clinical pipeline is derived from four different platform technologies: (1) Orascovery, based on nonabsorbed P-glycoprotein inhibition, (2) Src kinase inhibition, (3) T-cell receptor-engineered T-cells (TCR-T), and (4) arginine deprivation therapy. Athenexs employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments. Athenex has offices in Buffalo and Clarence, New York; Cranford, New Jersey; Houston, Texas; Chicago, Illinois; Hong Kong; Taipei, Taiwan; multiple locations in Chongqing, China; Manchester, UK; Guatemala City, Guatemala and Buenos Aires, Argentina. For more information, please visit http://www.athenex.com.

Forward-Looking Statements

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. These forward-looking statements are typically identified by terms such as anticipate, believe, continue, could, estimate, evaluate, expect, foresee, guidance, intend, investigate, likely, may, plan, potential, predict, preliminary, prepare, potential, probable, project, promising, seek, should, will, would, and similar expressions. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the development stage of our primary clinical candidates and related risks involved in drug development, clinical trials, regulation, manufacturing and commercialization; our reliance on third partiesfor success in certain areas of Athenexs business; our history of operating losses and need to raise additional capital to continue as a going concern; our ability to integrate CIDALs assets into our existing operations; competition; intellectual property risks; risks relating to doing business inChina; the uncertainty of when, if at all, we will be able to resume producing API in ourChongqingplant; and the other risk factors set forth from time to time in ourSECfilings, copies of which are available for free in the Investor Relations section of our website athttp://ir.athenex.com/phoenix.zhtml?c=254495&p=irol-secor upon request from our Investor Relations Department. All information provided in this release is as of the date hereof and we assume no obligation and do not intend to update these forward-looking statements, except as required by law.

CONTACTSAthenex, Inc.:Jacqueline LiCorporate Development and Investor RelationsEmail: JacquelineLi@athenex.com

Investor Relations:Tim McCarthyManaging Director, LifeSci Advisors, LLCDirect: 212-915-2564

See the original post here:

Athenex Announces Superior Response and Survival with Lower Neuropathy of a Novel Oral Paclitaxel versus IV Paclitaxel in Treatment of Metastatic...

Read More...

Chemotherapy Induced Peripheral Neuropathy Market to Witness a Sluggish Growth Owing to Stringent Government Policies in 2019 – 2029 – Markets Gazette…

December 15th, 2019 7:45 am

Assessment of the Chemotherapy Induced Peripheral Neuropathy Market

The latest report on the Chemotherapy Induced Peripheral Neuropathy Market published by Persistence Market Research (PMR) is a valuable tool for established and upcoming market players to solidify their presence in Chemotherapy Induced Peripheral Neuropathy Market landscape. Further, by leveraging the real-time and result-driven insights included in the report, readers can formulate effective business strategies to gain an advantage in the competitive nature of the market.

The presented study suggests that the Chemotherapy Induced Peripheral Neuropathy Market is expected to attain a value of ~US$ XX by the end of assessment period and grow at a CAGR of ~XX% during the forecast period, 2019 2029. The underlying trends, growth opportunities, market drivers, and challenges faced by companies in the Chemotherapy Induced Peripheral Neuropathy Market are analyzed in detail.

Exciting Prices for New Customers!!!Click HERE To get SAMPLE PDF (Including Full TOC, Table & Figures) at https://www.persistencemarketresearch.co/samples/30209

Vital Information Included in the Report:

The competitive landscape chapter of the report provides valuable insights related to the business prospects of some of the leading companies in the Chemotherapy Induced Peripheral Neuropathy Market. The product portfolio, pricing structure, revenue growth, and footprint analysis of each market players are included in the report.

Important Queries Related to the Chemotherapy Induced Peripheral Neuropathy Market Addressed in the Report

The dynamics of the Chemotherapy Induced Peripheral Neuropathy Market across major geographical regions are included in the report and represented in the study. In addition, to provide a frictionless reading experience the data is depicted using informative graphs and other graphical illustrations.

Get Access To TOC Covering 200+ Topics at https://www.persistencemarketresearch.co/toc/30209

key players and product offerings

Request Customized Report As Per Your Requirements athttps://www.persistencemarketresearch.co/request-customization/30209

What Makes PMR Different?

About us:

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact us:

305 Broadway, 7th FloorNew York City, NY 10007United StatesPh.no. +1-646-568-7751E-mail id- Website:

Read more from the original source:

Chemotherapy Induced Peripheral Neuropathy Market to Witness a Sluggish Growth Owing to Stringent Government Policies in 2019 - 2029 - Markets Gazette...

Read More...

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2025 – Industry…

December 15th, 2019 7:45 am

A profound analysis of the industry based on the "Chemotherapy Induced Peripheral Neuropathy Treatment Market" all over the world is named as Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Report. The research report assesses the current as well as the upcoming performance of the Chemotherapy Induced Peripheral Neuropathy Treatment market, in addition to with newest trends in the market. The major player of the Chemotherapy Induced Peripheral Neuropathy Treatment market (Aptinyx, Asahi Kasei Pharma, Regenacy Pharmaceuticals, MAKScientific, Metys Pharmaceuticals, Nemus Bioscience, PledPharma, Sova Pharmaceuticals, DermaXon, Immune Pharmaceuticals, Kineta, Krenitsky Pharmaceuticals, PeriphaGen, Apexian Pharma, WinSanTor, Solasia Pharma)are also included in the market report. The report forecasts the future of the Chemotherapy Induced Peripheral Neuropathy Treatment market on the basis of this evaluation.

The research analysis for Chemotherapy Induced Peripheral Neuropathy Treatment market comprises each and every feature of the market all over the world, which starts from the Chemotherapy Induced Peripheral Neuropathy Treatment market description and ends on the Chemotherapy Induced Peripheral Neuropathy Treatment market segmentation (Calcium Channel 2-delta Ligands, Antidepressants, Opioids, Others). In addition to this, each section of the Chemotherapy Induced Peripheral Neuropathy Treatment market is categorized and evaluated on the basis of goods, the end-user clients of the Chemotherapy Induced Peripheral Neuropathy Treatment market, and the employment of the products. The geographical categorization of the Chemotherapy Induced Peripheral Neuropathy Treatment market (Platinum Agents, Taxanes, Vinca Alkaloids, Others) has also been evaluated thoroughly in the report.

Ask for sample link here: https://www.intenseresearch.com/market-analysis/global-chemotherapy-induced-peripheral-neuropathy-treatment-market-2019.html#request-sample

The Chemotherapy Induced Peripheral Neuropathy Treatment perusers will discover this report exceptionally advantageous in the comprehension of the Chemotherapy Induced Peripheral Neuropathy Treatment showcase in the nitty-gritty. The angles and data are spoken to in the Chemotherapy Induced Peripheral Neuropathy Treatment report utilizing figures, structured presentations, pie graphs, and other visual portrayals. This escalates the Chemotherapy Induced Peripheral Neuropathy Treatment pictorial portrayal and furthermore helps in getting the Chemotherapy Induced Peripheral Neuropathy Treatment business actualities much better. The Chemotherapy Induced Peripheral Neuropathy Treatment advertise is probably going to develop at a noteworthy CAGR. The principle goal of the Chemotherapy Induced Peripheral Neuropathy Treatment report is to direct the client to comprehend the Chemotherapy Induced Peripheral Neuropathy Treatment advertise as far as its definition, order, Chemotherapy Induced Peripheral Neuropathy Treatment showcase potential, most recent patterns, and the difficulties that the Chemotherapy Induced Peripheral Neuropathy Treatment advertises is confronting.

Questions replied in this Chemotherapy Induced Peripheral Neuropathy Treatment report: https://www.intenseresearch.com/market-analysis/global-chemotherapy-induced-peripheral-neuropathy-treatment-market-2019.html

1. What will the Chemotherapy Induced Peripheral Neuropathy Treatment advertise projection and what will the advancement rate by 2024?

2. What are the major Chemotherapy Induced Peripheral Neuropathy Treatment advertise designs?

3. What is the development of driving components of the Chemotherapy Induced Peripheral Neuropathy Treatment industry?

4. What are the snags being developed to the Chemotherapy Induced Peripheral Neuropathy Treatment showcase?

5. Who are the Chemotherapy Induced Peripheral Neuropathy Treatment driving sellers in a market?

6. What are the market space and limitations by the Chemotherapy Induced Peripheral Neuropathy Treatment key sellers?

7. What are the Chemotherapy Induced Peripheral Neuropathy Treatment driving sellers quality through SWOT and PESTEL consider?

Another area of the Chemotherapy Induced Peripheral Neuropathy Treatment advertise report uncovers the procedure of creation. Be that as it may, this procedure gauges nitty-gritty Chemotherapy Induced Peripheral Neuropathy Treatment think about with respect to assembling cost which incorporates crude stock, and diverse providers for modern offices.

Enquire about our report with our industry authority:

Overall Chemotherapy Induced Peripheral Neuropathy Treatment Market Report Importance:

Our report significantly fixates around genuine research on each part and its general result on the Chemotherapy Induced Peripheral Neuropathy Treatment showcase advance.

The objective gathering of watchers of the Chemotherapy Induced Peripheral Neuropathy Treatment report acclimatizes new wannabes planning to wind up an expansive comprehension of the business, masters, monetary establishments, real accomplices, profitability, Chemotherapy Induced Peripheral Neuropathy Treatment wholesalers, and industry organization.

To get the examination techniques those are being gathered by Chemotherapy Induced Peripheral Neuropathy Treatment driving individual associations.

To have the misgiving without obstacles Chemotherapy Induced Peripheral Neuropathy Treatment stance and a probability for the market.

Thanks for reading this article; you can also get individual chapter wise section or region wise report versions like North America, Europe or Asia.

About Us Market and Research are a trusted brand in the research industry with the capability of commissioning complex projects within a short span of time with a high level of accuracy. At Market and Research, we believe in building long term relations with our clients. Our services cover a broad spectrum of industries including Energy, Chemicals and Materials, Automotive and Aerospace.

Contact Us: Market and Research United States

Read the original here:

Global Chemotherapy Induced Peripheral Neuropathy Treatment Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2025 - Industry...

Read More...

Neuropathy Pain Treatment Market 2019 Share, Growth, Region Wise Analysis of Top Players, Application, Driver, Existing Trends and Forecasts 2026 -…

December 15th, 2019 7:45 am

Latest market research report On Neuropathy Pain Treatment Market from Ample Market Research covers market overview- defines characteristics, size and growth, segmentation, regional breakdowns, competitive landscape, market shares, trends and strategies for the Neuropathy Pain Treatment industry. The market size section gives the market revenues, covering both the historic data of the market and forecasting the future. Drivers and restraints are studied with respect to external factors influencing the growth of the market. Industry segmentations breaks down the key sub-sectors which make up the market. Additionally, the report also highlights market entry strategies for various companies across the globe. Some of the key players operating in this market include Pfizer, Depomed, Eli Lilly, Endo, Grnenthal Group, Arbor Pharmaceuticals.

Get a complete & Professional sample PDF of the Neuropathy Pain Treatment market report at https://www.amplemarketreports.com/sample-request/global-neuropathy-pain-treatment-market-1248476.html

The report provides insightful and comprehensive information in consideration of the different industry pioneers, including their revenue details, technological advancements, innovations, key developments, SWOT analysis, mergers & applications, future strategies, and market footprint. On the basis of segmentation, the market has been classified into product type, the technologies used, end-user, industry vertical, and geography.

Key companies profiled in this report are Pfizer, Depomed, Eli Lilly, Endo, Grnenthal Group, Arbor Pharmaceuticals and more. These companies are profiled in terms of company basic details, business overview, product knowledge, historical revenue, and recent developments.

The report offers thorough information about the overview and the scope of the Neuropathy Pain Treatment market along with its drivers, restraints, and trends. It also classifies the market into different segments such as by type, by applications and by-product

On the basis of product, this report displays the production, revenue, price, market share, and growth rate of each type, primarily split into Calcium channel alpha 2-delta ligands, Serotonin-norepinephrine reuptake inhibitors, Others.

In terms of region, this research report covers almost all the major regions across the globe such as Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Oceania], Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland], North America[United States, Canada, Mexico], Middle East & Africa[GCC, North Africa, South Africa], South America[Brazil, Argentina, Columbia, Chile, Peru]

Split by application, this report focuses on consumption, market share and growth rate of Neuropathy Pain Treatment in each application.

Access full Report Description, TOC, Table of Figure, Chart, etc. @ https://www.amplemarketreports.com/report/global-neuropathy-pain-treatment-market-1248476.html

The study objectives are:

To analyze and research the Neuropathy Pain Treatment market status and future forecast? involving, production, revenue, consumption, historical and forecast.

To present the key manufacturers, production, revenue, market share, and development plans in the next few years.

To segment the breakdown data by regions, type, manufacturers, and applications of Neuropathy Pain Treatment market.

To analyze the global keyword market opportunity, drivers, challenge, and restraints.

To identify significant trends, influence factors of Neuropathy Pain Treatment market.

To evaluate each submarket with respect to individual growth trends and their contribution to the market.

To examine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

This report can be customized to meet your requirements. Please connect with our sales team who will ensure that you get a report that suits your needs.

https://www.amplemarketreports.com/enquiry-before-buy/global-neuropathy-pain-treatment-market-1248476.html

Lastly, the Neuropathy Pain Treatment Market study provides essential information about the major challenges that are going to influence market growth. The report additionally provides overall details about the business opportunities to key stakeholders to expand their business and capture revenues in the precise verticals. The report will help the existing or upcoming companies in this market to examine the various aspects of this domain before investing or expanding their business in the Neuropathy Pain Treatment market.

About Ample Market Research

Ample Market Research provides comprehensive market research services and solutions across various industry verticals and helps businesses perform exceptionally well. Attention to detail, consistency, and quality are elements we focus on. However, our mainstay remains to be knowledge, expertise, and resources to make us industry players.

Our end goal is to provide quality market research and consulting services to customers and add maximum value to businesses worldwide. We desire to delivery reports that have the perfect concoction of useful data.

Our mission is to capture every aspect of the market and offer businesses a document that makes solid grounds for crucial decision making.

Contact Us

Ample Market Research & Consulting Private Limited

William James

Media & Marketing Manager

Address: 3680 Wilshire Blvd, Ste P04 1387 Los Angeles, CA 90010

Call: +1 (530) 868 6979

Email: [emailprotected]

Website: http://www.amplemarketreports.com

Read the original here:

Neuropathy Pain Treatment Market 2019 Share, Growth, Region Wise Analysis of Top Players, Application, Driver, Existing Trends and Forecasts 2026 -...

Read More...

Global Neuropathy Pain Treatment Market 2019 by Manufacturers, Countries, Type and Application, Forecast to 2025 – World Industry Reports

December 15th, 2019 7:45 am

The research report Neuropathy Pain Treatment Market Global Industry Analysis 2019 2025 offers precise analytical information about the Neuropathy Pain Treatment market. The report identifies top players in the global market and divides the market into several parameters such as major drivers market strategies and imposing growth of the key players. Worldwide Neuropathy Pain Treatment Industry also offers a granular study of the market dynamics, segmentation, revenue, share forecasts and allows you to make superior business decisions. The report serves imperative statistics on the market stature of the prominent manufacturers and is an important source of guidance and advice for companies and individuals involved in the Neuropathy Pain Treatment industry.

This Neuropathy Pain Treatment market report bestows with the plentiful insights and business solutions that will support our clients to stay ahead of the competition. This market report contains categorization by companies, region, type, and application/end-use industry. The competitive analysis covered here also puts light on the various strategies used by major players of the market which range from new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and many others that leads to increase their footprints in this market. The transparent research method carried out with the right tools and methods makes this Neuropathy Pain Treatment market research report top-notch.

Interesting? Apply for a sample report: http://www.marketresearchstore.com/report/global-neuropathy-pain-treatment-market-2018-by-manufacturers-353817#RequestSample 

Competitive Landscape

Global Neuropathy Pain Treatment market is highly split and the major players have used numerous tactics such as new product launches, acquisitions, innovation in products, expansions, agreements, joint ventures, partnerships, and others to increase their footprints in this market.

Key players profiled in the report include: Pfizer, Depomed, Eli Lilly, Endo, Grnenthal Group, Arbor Pharmaceuticals

Market Segmentation

Neuropathy Pain Treatment Market report segmentation on Major Product Type:Calcium Channel Alpha 2-delta Ligands, Serotonin-norepinephrine Reuptake Inhibitors, Others

Market by Application: Here, various application segments of the global Neuropathy Pain Treatment market are taken into account for the research study.

Retail Pharmacies, Hospitals, Others

Enquire Here For Queries Or Report Customization: http://www.marketresearchstore.com/report/global-neuropathy-pain-treatment-market-2018-by-manufacturers-353817#InquiryForBuying

Regional Analysis

The Neuropathy Pain Treatment market report keenly emphasizes on industrial affairs and developments, approaching policy alterations and opportunities within the market. The regional development methods and its predictions are explained in every key point that specifies the general performance and issues in key regions such as North America, Europe, Asia Pacific, Middle East, South America, and Middle East & Africa (MEA). Various aspects such as production capability, demand, product value, material parameters and specifications, distribution chain and provision, profit and loss, are explained comprehensively in the market report.

Key Questions Answered in Global Neuropathy Pain Treatment Market Report:-

What will the market growth rate, overview, and analysis by type of global Neuropathy Pain Treatment Market in 2026?

What are the key factors driving, analysis by applications and countries Global Neuropathy Pain Treatment Market?

What are dynamics, this summary includes analysis of the scope and price analysis of top players profiles of Global Neuropathy Pain Treatment Market?

Who are the opportunities, risk and driving forces of the global Neuropathy Pain Treatment Market?

Who are the opportunities and threats faced by the vendors in the Global Neuropathy Pain Treatment Market?

What are the Global Neuropathy Pain Treatment market opportunities, market risk and market overview of the Market?

Thanks for reading this article, you can also get individual chapter wise section or region wise report versions like North America, Europe or Asia. Also, If you have any special requirements, please let us know and we will offer you the report as you want.

More:

Global Neuropathy Pain Treatment Market 2019 by Manufacturers, Countries, Type and Application, Forecast to 2025 - World Industry Reports

Read More...

Health watch: 5 things to know about chemotherapy – StarNewsOnline.com

December 15th, 2019 7:45 am

New medicines and treatments can often help patients better tolerate the sometimes harsh side effects of chemo

Chemotherapy, or chemical treatment, is often recommended as a treatment for a variety of cancers as it uses powerful chemicals to kill fast-growing cells, such as cancer cells, in ones body. Particularly for cancer that has spread to different parts of the body beyond the original tumor, chemotherapy can be effective as it can work throughout the whole body. According to the American Cancer Society, the three main goals for using chemotherapy in cancer treatment are to cure cancer, to control the disease if a cure isnt possible and palliation, to ease symptoms.

Dr. Lindsey Prochaska, DO, a medical oncologist with NHRMC Physician Group - Cape Fear Cancer Specialists, and Katie Evans, an oncology clinical pharmacist at NHRMC, have shared some information about this common cancer-fighting treatment, often called chemo. Prochaska treats patients at Cape Fear Cancer Specialists office in Leland and at New Hanover Regional Medical Centers Zimmer Cancer Center, and Evans collaborates with the oncology teams and patients at the Zimmer Cancer Center.

1) Chemotherapy can be used alone or along with other treatments

Sometimes chemotherapy is the only treatment a patient may need to treat a cancer, other times it may be used along with other forms of treatment.

"Chemotherapy can be used after surgery, before surgery, or even in the metastatic non-curable setting for control of cancer, said Prochaska. In the setting in which surgery removes a cancer, chemotherapy is often used before or after the surgery to rid the bloodstream of cells to reduce recurrence.

Some cancers respond to chemotherapy better than others, and Prochaska said chemotherapy may not be recommended in some circumstances.

More aggressive cancers sometimes respond better to chemotherapy than slow growing ones, she said. Very few cancers have no role for chemotherapy, but if a cancer is caught at a very early stage chemo may not be recommended.

As for if chemotherapy can sometimes provide a complete cure, Prochaska said, Absolutely. When given before or after surgery cure is commonly the goal, she said.

2) Chemotherapy drugs can be taken orally or received through ones veins

Chemotherapy is most often administered intravenously (IV), although, there are some oral chemotherapy treatment options, Evans said. Chemotherapy is administered by chemotherapy certified nurses in the infusion center, whereas, the oral options patients can self-administer following safety precautions for hazardous medications.

3) Chemotherapy can also treat other conditions

Chemotherapy is mostly only used for cancer, but there are some targeted therapies and conventional chemotherapies that treat autoimmune diseases, like lupus and rheumatoid arthritis, Prochaska said.

4) Chemotherapy can reduce chances of a cancer returning

The side effects of chemo can be harsh, but many times when recommended, its to increase the chances of cure, Prochaska said. Chemo can reduce the chances of recurrence 25-50% -- sometimes higher.

5) Side effects are common with chemotherapy

It is true that most systemic chemotherapy can affect both healthy and cancer cells in causing cell death, Evans said. Chemotherapy targets fast growing cells inside of the body which can be both cancer cells and healthy cells. Herein lies the potential for side effects. With newer, more targeted therapy and immunotherapy coming into use, we have seen the potential for side effects to lessen as compared to traditional, systemic chemotherapy.

Evans said these targeted therapies still have side effects that are manageable by an oncologist.

As clinical oncology pharmacists we counsel patients on the side effects they may experience, timeline, and management of the particular side effects with the chemotherapy regimen, she said.

Evans said some common side effects of chemotherapy include lowering blood counts, nausea, vomiting, gastrointestinal disturbances, peripheral neuropathy, hair loss, appetite and taste changes.

Side effects from chemotherapy are common, but can be managed with supportive care medications, Evans said. Once chemotherapy is completed, many side effects will resolve, though we know that some side effects like hair loss and neuropathy will take months to resolve.

Evans said side effects with chemotherapy treatment also differ in the time of onset. The effects on blood cell counts are relatively soon after chemotherapy has begun, hair loss is usually between 2-3 weeks after chemotherapy, and neuropathy may take several weeks before noticing.

Contrary to what some may think, Evans said not all types of chemotherapy cause hair loss.

Prochaska said medications have made a difference regarding some side effects.

Chemotherapy premedications and postmeds have come a long way, Prochaska said. Many people tolerate chemotherapy much better than expected now that we have medications that can help control nausea and vomiting.

Contact the newsroom at 910-343-2384 or Breakingnews@StarNewsOnline.com.

The rest is here:

Health watch: 5 things to know about chemotherapy - StarNewsOnline.com

Read More...

ASH 2019: Brentuximab Vedotin in Combination with Nivolumab in Frontline and R/R Hodgkin Lymphoma – OncoZine

December 15th, 2019 7:45 am

Updated and long-term follow-up analyses from two clinical trials evaluating brentuximab vedotin (Adcetris; Seattle Genetics/Takeda) and nivolumab (Opdivo; BristolMyers Squibb) in frontline Hodgkin lymphoma patients aged 60 years and older and in relapsed or refractory classical Hodgkin lymphoma were presented at the 61st annual meeting of the American Society of Hematology (ASH) taking place December 7-10, 2019 in Orlando, Florida.

According to the American Cancer Society, approximately 8,110 cases of Hodgkin lymphoma will be diagnosed in the United States during 2019 and 1,000 will die from the disease. Approximately half of all newly diagnosed Hodgkin lymphoma patients have Stage III/IV disease. According to the Lymphoma Coalition, over 62,000 people worldwide are diagnosed with Hodgkin lymphoma each year and approximately 25,000 people die each year from this cancer.

Antibody-drug conjugateBrentuximab vedotin is an antibody-drug conjugate or ADC directed to CD30, a defining marker of classical Hodgkin lymphoma. The drug includes an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE). The ADC employs a linker system that is designed to be stable in the bloodstream but to release MMAE upon internalization into CD30-expressing tumor cells.

Antibody-drug Conjugates are highly targeted biopharmaceutical drugs that combine monoclonal antibodies specific to surface antigens present on particular tumor cells with highly potent anti-cancer agents linked via a chemical linker.

With five approved drugs on the market, ADCs have become a powerful class of therapeutic agents in oncology and hematology.

Continued evaluationWe continue to evaluate brentuximab vedotin in combination with novel therapies, such as checkpoint inhibitors, with the goal of identifying new options for CD30-expressing lymphomas where there is high unmet need, said Roger Dansey, MD, Chief Medical Officer at Seattle Genetics.

The data presentations at the annual meeting reinforces our strong commitment to the brentuximab vedotin clinical development program, potentially moving into new patient populations and novel combination treatment strategies, Dansey added.

Frontline therapyData were presented from an updated analysis from the phase II clinical trial evaluating brentuximab vedotin in combination with nivolumab as frontline therapy for Hodgkin lymphoma patients aged 60 years and older. Data were reported from 21 patients, and the median age was 72 years. The majority of patients (76%) had stage III/IV disease at the time of diagnosis.

These results were highlighted in an oral presentation by Christopher A. Yasenchak, MD, Willamette Valley Cancer Institute and Research Center/US Oncology Research, Oregon. [1]

The trial included 19 response-evaluable patients, 18 patients (95%) had an objective response, including 13 patients (68%) with a complete response and five patients (26%) with a partial response.

All response-evaluable patients experienced tumor reduction (complete response + partial response + stable disease) following treatment with brentuximab vedotin in combination with nivolumab. Median duration of response was not yet reached and the maximum duration of response was 22 months and ongoing (95% CI: 7.06, -).

The most common treatment-related adverse events of any grade occurring in at least 20% of patients were fatigue, diarrhea, pyrexia, infusion related reaction, peripheral motor neuropathy, peripheral sensory neuropathy and increase in lipase.

One treatment-related serious adverse event was pyrexia. Fifty-seven percent of patients (12/21) had at least one treatment-related adverse event greater than or equal to Grade 3, most commonly increase in lipase (24%, 5/21), peripheral motor neuropathy and peripheral sensory neuropathy (each 14%, 3/21), and fatigue and hyponatremia (each 10%, 2/21).

These data suggest that brentuximab vedotin + nivolumab is an active treatment with an encouraging CR rate (72%) and appears well tolerated. The results also suggest that with further follow-up and validation, treatment with brentuximab vedotin + Nivo may improve patient outcomes.

Relapsed or Refractory Hodgkin LymphomaA second presentation reported data from 93 patients with relapsed or refractory classical Hodgkin lymphoma after failure of frontline therapy who received the combination regimen of brentuximab vedotin plus nivolumab.

After completion of the fourth cycle of treatment, patients were eligible to undergo an autologous stem cell transplant (ASCT). The median age of patients was 34 years.

These results were highlighted in an oral presentation by Alison J. Moskowitz, MD, Memorial Sloan Kettering Cancer Center, New York, NY. [2]

The study results of this trial showed that of the 91 treated patients, 85% (77/91) had an objective response, including 67% (61/91) with a complete response, 16 patients with a partial response and six patients had stable disease.

From the ninety-one treated patients, sixty-seven patients received an ASCT per trial protocol with no additional salvage therapy. For all treated patients, the two-year progression-free survival (PFS) was 79% (95% CI: 68%, 87%). For the 67 patients who received an ASCT per trial protocol, the two-year PFS was 92% (95% CI: 80%, 97%). Median follow-up for all treated patients was 24.2 months (range 1.8-41.7) and the median PFS was not reached. Estimated overall survival at two years was 94% (95% CI: 85%, 97%) and median overall survival was not yet reached.

Peripheral immune signatures were consistent with an activated T-cell response. Prior to ASCT, the most common adverse events of any grade occurring in more than 20% of patients were nausea, infusion related reaction, fatigue, diarrhea, pruritus, headache, vomiting and pyrexia. Other adverse events included peripheral neuropathy in 16 patients (18%) and neutropenia in six patients (7%). Two patients (2%) discontinued treatment due to adverse events, Grade 3 peripheral neuropathy and increased gamma-glutamyltransferase. Serious adverse events occurred in 14 patients (15%), including pneumonia, pneumonitis and pyrexia (two patients each); and Grade 3 Guillain-Barre syndrome (one patient).

Reference[1] Yasenchak CA, Bordoni R, Yazbeck V, Patel-Donnelly D, Anderson T, Larson T, Newhook T, Mei M, et al. Phase II Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged 60 Years. 61st annual meeting of the American Society of Hematology (ASH). Program: Oral and Poster Abstracts. Type: Oral. Abstract 237. Session: 624. Hodgkin Lymphoma and T/NK Cell LymphomaClinical Studies: Immunotherapy Approaches in Hodgkin Lymphoma Hematology Disease Topics & Pathways: Diseases, Biological, antibodies, Therapies, Non-Hodgkin Lymphoma, T-Cell Lymphoma, Lymphoid Malignancies.[Abstract][2] Moskowitz AJ, Advani R, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Christian BA, et al. Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase I/II Study. 61st annual meeting of the American Society of Hematology (ASH).Program: Oral and Poster AbstractsType: Oral Abstract 238. Session: 624. Hodgkin Lymphoma and T/NK Cell LymphomaClinical Studies: Immunotherapy Approaches in Hodgkin Lymphoma. Hematology Disease Topics & Pathways:Diseases, Biological, Therapies, Hodgkin Lymphoma, checkpoint inhibitors, immunotherapy, Lymphoid Malignancies. [Abstract]

Read more here:

ASH 2019: Brentuximab Vedotin in Combination with Nivolumab in Frontline and R/R Hodgkin Lymphoma - OncoZine

Read More...

Medical News Today: Lung cancer complications: Signs, treatment, and outlook – Stock Daily Dish

December 15th, 2019 7:45 am

Cancer is a disease caused by unhealthy cells inside the body growing out of control. Lung cancer is the uncontrolled growth of abnormal cells that start off in one or both lungs.

In the United States, is the form of . It is also the most common cause of cancer death in the U.S.

Contents of this article:

Lung cancer can cause a number of complications in the lungs and in other parts of the body. Here are some of the most common complications:

Some of the more common lung cancer symptoms are caused by complications in the lungs.

According to , these complications can lead to the following symptoms:

Pneumonia is a possible symptom of complications in the lungs caused by cancer.

is numbness and tingling feelings in the hands and feet due to damaged nerve tissue. It can be a .

Neuropathy is caused by tumors that grow near the nerves in the arm or shoulder. A compresses the nerves leading to pain and weakness.

This is the in the membrane that covers the lungs. The fluid can then press against the lungs causing breathlessness.

Lung cancers can sometimes affect the heart when they develop near it or close to major blood vessels. This can cause fluid to press against the heart, which may lead to a number of issues.

These issues include:

Depending on its location, a tumor may block a persons airways or food pipe.

A tumor may grow into an airway in the lung and block it. This may lead to other issues, such as pneumonia or shortness of breath.

Lung cancers that grow near a persons food pipe can cause complications, making it difficult for the person to swallow.

Cancers near a foodpipe may lead to a person feeling pain when food passes through to their stomach.

Another serious complication of lung cancer is that it may spread to other parts of the body. Some lung cancer cells can travel through the lymphatic system or through the bloodstream.

If this happens, the cells can become lodged somewhere else in the body. Cancerous cells can then grow in these new locations, causing further cancers.

According to , lung cancer is most likely to spread to:

There are a number of ways to treat all of these different complications. The choice of treatment will vary depending on a number of factors, which include the type of complication, the age, and the general health of the patient.

Here are different treatments for the variety of complications listed above:

Numbness and tingling in the hands or feet may be treated with medication.

Neuropathy as a complication of lung cancer can lead to discomfort. There are many ways to treat the symptoms of neuropathy, including:

Pleural effusion can be treated by slowly draining away the fluid. In order to do this, a tube is inserted into the chest through a small cut.

A person may spend a few days in hospital after this treatment. If the fluid builds up again, they may need to have it drained a further time.

A person with pleural effusion may also have one of the following procedures:

Heart complications can occur if fluid presses against blood vessels because of a tumor. This can be treated in the following ways:

There are a number of procedures to treat lung cancer if it blocks a persons airways. These include the following:

Complications caused by lung cancer can occur over time. They tend to appear as the disease develops.

If a persons lung cancer is detected early, then they have a much higher chance of surviving the disease. Its important for a person to understand the symptoms so that they can get an early diagnosis.

Unfortunately, most cases of lung cancer are diagnosed in the later stages. This is because many of the symptoms or complications of the disease tend not to occur until the cancer is advanced.

Therefore, the individual outlook depends on a number of factors including the type of cancer, how far it has developed, and the persons age and general health.

Written by Adam Rowden

Follow this link:

Medical News Today: Lung cancer complications: Signs, treatment, and outlook - Stock Daily Dish

Read More...

Care Coordination and Precision Medicine Improve Early Diagnoses – HealthPayerIntelligence.com

December 15th, 2019 7:44 am

December 12, 2019 -Payers are using coordinated care and precision medicine to make diagnoses more quickly and ensure a strong treatment plan for severe and chronic disease management.

Early detection of chronic and severe diseases can mean the difference between life and death. It can also mean the difference between affordable therapies and crippling medical bills.

A March 2018 study found that early cancer diagnosis could result in significant cost savings nationally. Researchers looked at 17 types of cancer and estimated that early detection could save, conservatively, $26 billion nationally.

Recognizing what is at stake, payers take different approaches to catching severe or chronic illnesses in their formative stages.

Coordinated care is a simple, well-tested method for both chronic disease prevention and chronic disease management.

READ MORE: Chronic Disease Coordinated Care May Not Impact Pediatric Spending

Humana recently announced that it would pursue a traditional approach to ensure that patients in danger of chronic kidney and end of life renal disease find out early and get the support they need.

Humana will task skilled provider teams with catching these diseases earlier and implementing personalized treatments.

This coordinated care strategy builds a team of nephrologists, nurses, dietitians, and social workers from one of Humanas two partnerseither Monogram Health or Somatus, depending on geographic location.

The providers will work with the patients primary care physician to determine the best treatments and provide home healthcare options, patient education, and mental healthcare support through counseling.

This multidisciplinary approach will focus on detecting kidney disease earlier, slowing disease progression, and utilizing therapies that enable members to receive care in the convenience of their own home, said William Shrank, MD, MPHS, Humanas chief medical and corporate affairs officer.

READ MORE: Cigna and MSK Start Value-Based, Coordinated Cancer Care Program

Through this collaboration, we will strengthen care coordination for Humana members with kidney disease. Our partnerships will offer customized care options, and will empower patients with education and engagement tools to better manage their condition.

In February, Humana took a similar approach with its oncology program, enhancing its coordinated care strategy and using analytics to ensure quality care.

With new advancements every day in genetic therapies, precision medicine is another method payers use to ensure that patients receive a quick diagnosis and the best treatment plan.

CVS Health launched an oncology care program called Transform Oncology Care, which uses precision medicine to identify and treat cancer patients. The program is rolling out to Aetna members in 12 states but is also available for use by other payers.

Due to CVS Healths geographic and data footprint, it can assess the likelihood that a patient will get cancer. With that information, the patients provider can intervene early on to pursue preventive care, screenings, or therapies.

READ MORE: Precision Medicine Challenges Persist, Aetna Leads Response

When it comes to identifying the appropriate therapies, the program allows providers to use genetics to identify the best course of treatment for a patient recently diagnosed with cancer.

Timing in cancer care is everything and when a patient does not get started on the right treatment it can result in progression and higher costs, said Alan Lotvin, MD, executive vice president and chief transformation officer at CVS Health.

We are the first company working to make the latest in precision medicine accessible to more patients and further empower informed treatment decision-making based on a patient's genetic profile to give them the best chance for successful treatment and improved quality-of-life.

Working in coordination with its third-party vendor, Tempus, CVS Healths new program will enable patients to undergo a broad-panel gene sequencing test once diagnosed to determine the best treatment. This is ideal not only for patients in early stages of cancer, but especially for patients in more advanced stages who need to start treatment as soon as possible.

Because genomic sequencing has certain eligibility requirements, providers are not always aware that gene sequencing is an option open to their patient.

In order to ensure that oncologists prescribe gene sequencing to eligible patients, CVS Health introduced a web-based provider portal into its e-prescribing software which allows oncologists to see the patients eligibility for the broad-panel gene sequencing tests among other functions.

For those who qualify, the program identifies the best treatment options based on genetic makeup. It also alerts providers to potential clinical trials that patients can enroll in and makes the enrollment process easier and faster.

The program integrates National Comprehensive Cancer Network guidelines which are constantly updated for the most recent suggested prescribing and treatment options.

Critically, this service can be employed at the point of detection, so treatments can be identified immediately, and a therapeutic strategy quickly determined.

CVS Health combines this digital solution with a nurse-led coordinated care team to continue quality of care after the diagnosis.

This service is available for only fully insured commercial members.

Among its other chronic disease management developments, earlier this year, CVS Health used preventive care to improve diabetes treatment.

The rest is here:
Care Coordination and Precision Medicine Improve Early Diagnoses - HealthPayerIntelligence.com

Read More...

Proteostasis Therapeutics to Initiate First Ever Personalized Medicine-Based Clinical Trial, CHOICES, in European CF Patients with Genotypes…

December 15th, 2019 7:44 am

BOSTON, Dec. 11, 2019 /PRNewswire/ --Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF), today announced positive, initial ex-vivo results of PTI's proprietary cystic fibrosis transmembrane conductance regulator (CFTR) modulators, PTI-801, PTI-808, and PTI-428, in individuals with CF who are ineligible for the current standard of care CFTR modulator therapies due to their genotype. The data are part of a pan-European strategic initiative, known as HIT-CF (Human Individualized Therapy of CF), which seeks to accelerate the development of, and access to, personalized therapies for CF patients, beginning with those for whom no currently approved CFTR modulator therapy is indicated.

HIT-CF is sponsored by the European Commission Horizon 2020 program, in which CF-Europe, a patient organization representing more than 48,000 individuals with CF, collaborates and with the European Cystic Fibrosis Society Clinical Trial Network (ECFS-CTN), which is recruiting adult CF patients into the ex- vivo study through its 43 clinical trial centers. HIT-CF collects tissue samples from CF patients and develops organoids, or miniaturized organs, that are genetically identical to the patient donor, and share the same micro-anatomy as the organ from which they were derived.

As of today, rectal organoids from over 300 subjects have been collected for functional profiling and of those, 65 have been tested for response to PTI's investigational drugs. Early results support the initiation of enrollment of responding subjects into HIT-CF's clinical trial known as "CHOICES" (Crossover trial based on Human Organoid Individual response in CF - Efficacy Study), which is designed to evaluate the translation of organoid ex-vivo response to potential clinical benefit, such as changes in FEV1 and sweat chloride. CHOICES, which is expected to initiate in mid-2020, will be the first ever personalized medicine-based study in CF, with initial data expected by the end of 2020. Fully funded by the HIT-CF, this trial is a placebo controlled, double blind, crossover study with an 8-week treatment period and 6 months of uninterrupted dosing. The results may serve as the basis for a potential Marketing Authorization Application with the European Medicines Agency (EMA) in 2021 through a novel regulatory pathway which is being pursued jointly by Proteostasis and HIT-CF. The CHOICES clinical study is part of PTI's broader clinical development strategy for its CFTR modulator candidates that is already separately funded for the common genotypes.

Results from the HIT-CF project to date will be presented at the Keystone Symposia on Tissue Organoids titled "Tissue Organoids as Models of Host Physiology and Pathophysiology of Disease (J1)" taking place on January 19-23, 2020 in Vancouver, BC, Canada.

"Proteostasis is honored to have been invited to participate in the HIT-CF project and is the only company in the group with a combination of novel CFTR modulators being tested ex-vivo. We are very enthusiastic about the progress of the study," said Geoffrey Gilmartin, M.D., M.M.Sc., Chief Medical Officer of Proteostasis Therapeutics. "In Europe alone, there are more than 2,300 adult patients whose genotypes render them ineligible for approved CFTR modulators and exclude them from participating in clinical trials with this drug class. This project's proposed personalized medicine approach is paving a potential new way to develop and provide access to novel CFTR modulators for patients with the most dire need for treatment options that target the cause of the disease. Additionally, based on an individual patient's disease phenotype and not just the genetic designation, this approach could also create a new path towards more effective treatment for all people with CF."

"The inequality in access to CFTR modulators is an acute problem across Europe where 1 in 5 individuals do not have a F508del mutation. In addition, drug reimbursement policies are leading to an ever-growing gap between patients who do, and those who do not have effective treatment options," said Christiane De Boeck, Work Package Leader at HIT-CF, and Former President of ECFS. "At HIT-CF Europe, we believe that novel strategies such as personalized medicine and development of new treatment options are central to addressing the inequality of access across the continent. We are thrilled with these initial results and look forward to providing additional updates."

About Organoids

Organoids are cell cultures that grow in a culture dish and look similar to the organ from which they are derived. Because organoids are made from stem cells, they contain the same mutations as the person from whom the biopsies are derived. Investigational drugs which target the basic defect of CF can be used in an organoid system to evaluate rare mutations where the drugs may have a positive effect.

Unlike in vitro systems such as human bronchial epithelial (HBE) cells, which are derived from lungs that have been removed from CF patients, or the engineered, rat-derived FRT cell line, the latter has resulted in false positive clinical results, rectal organoids are cultured from tissues obtained through a minimally invasive and painless procedure from donors who then become eligible to participate in a clinical study. Organoids can provide valuable insights for donors, including their likelihood of achieving improvements in pulmonary function and reductions in sweat chloride concentration with CFTR modulators based on the ex-vivo response to those drugs.1

About HIT-CF Europe

HIT-CF Europe is a research project which aims to provide better treatment and better lives for people with cystic fibrosis (CF) and rare mutations. To achieve this, drug candidates are first tested on patient-derived organoids in qualified laboratories across Europe. Subsequently, based on the measured signal in the organoids, a smaller group of patients will be invited to participate in a clinical trial with one or more investigational molecules from a participating pharmaceutical company.

All participating centers are part of the European Cystic Fibrosis Society Clinical Trial Network (ECFS-CTN). The project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement number 755021. For more information, visit http://www.hitcf.org.

About Proteostasis Therapeutics, Inc.

Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis and other diseases caused by dysfunctional protein processing. Headquartered in Boston, MA, the Proteostasis Therapeutics team focuses on identifying therapies that restore protein function. For more information, visit http://www.proteostasis.com.

Safe Harbor

To the extent that statements in this release are not historical facts, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "aim," "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Examples of forward-looking statements made in this release include, without limitation, statements regarding the expected presentation at an upcoming conference. Forward-looking statements made in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we, therefore cannot assure you that our plans, intentions, expectations or strategies will be attained or achieved. Such risks and uncertainties include, without limitation, our expectations regarding our participation in HIT-CF's pan-European strategic initiative,the potential of our proprietary combination therapies for the treatment of CF, the potential benefit of our proprietary combination therapies to patients, expected timing of patient enrollment in, data from, the completion of, and reporting top line results of our clinical studies and cohorts for our clinical programs, including our planned Phase 2 program and initiation of a pivotal or registrational study, the possibility final or future results from our drug candidate trials (including, without limitation, longer duration studies) do not achieve positive results or are materially and negatively different from or not indicative of the preliminary results reported by the Company (noting that these results are based on a small number of patients and small data set), uncertainties inherent in the execution and completion of clinical trials (including, without limitation, the possibility that FDA or other regulatory agency comments delay, change or do not permit trial commencement, or intended label, or the FDA or other regulatory agency requires us to run cohorts sequentially or conduct additional cohorts or pre-clinical or clinical studies), in the enrollment of CF patients in our clinical trials in a competitive clinical environment, in the timing of availability of trial data, in the results of the clinical trials, in possible adverse events from our trials, in the actions of regulatory agencies, in the endorsement, if any, by therapeutic development arms of CF patient advocacy groups (and the maintenance thereof), in the commercialization and acceptance of new therapies, and those set forth in our Annual Report on Form 10-K for the year ended December 31, 2018, our Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 and our other SEC filings. We assume no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACTS:

Investors: David Pitts / Claudia StyslingerArgot Partners212.600.1902 david@argotpartners.com/ claudia@argotpartners.com

Media:David RosenArgot Partners212.600.1902david.rosen@argotpartners.com

1Berkers et al, Rectal Organoids Enable Personalized Treatment of Cystic Fibrosis Cell Reports 26, 17011708,February 12, 2019

SOURCE Proteostasis Therapeutics, Inc.

Home

Originally posted here:
Proteostasis Therapeutics to Initiate First Ever Personalized Medicine-Based Clinical Trial, CHOICES, in European CF Patients with Genotypes...

Read More...

Over 70% of Orgs Say Precision Medicine Meets or Tops Expectations – HealthITAnalytics.com

December 15th, 2019 7:44 am

December 12, 2019 -Seventy-three percent of precision medicine adopters say these initiatives have neared or exceeded their expectations, with organizations using clinical analytics solutions and real-world data to meet their goals, according to a global survey from XIFIN and the Journal of Precision Medicine.

Approximately 59 percent of participants said that their EHR, EMR, or similar solutions did not meet or only partially met the needs of hands-on precision medicine users, indicating that success will require more advanced tools.

The fundamental design of EHRs makes them unsuitable for precision medicine programs because detailed patient data, such as biomarkers, are locked within a PDF, explained Nigel Russell, editor-in-chief of theJournal of Precision Medicine.

Physicians need real-time access to the patient data that will enable them to make the best patient care decisions, and today, investors and providers alike are looking for technologies that provide comprehensive clinical, diagnostic and financial data to ensure and build successful PMI programs.

The survey polled a total of 189 respondents, 62 percent of whom were from the US. The seniority of participants ranged from faculty or departments heads to board members and C-level executives.

Respondents said they are currently using provider-facing clinical analytics solutions, real-world data aggregation technology, business intelligence tools, and clinical data warehouse to advance their precision medicine initiatives, and that their frequency of use is higher than expected.

Just over ten percent of participants said they are currently using real-world data for disease insights or cohort studies, while just over nine percent are using real-world data to inform either clinical trial matching or peer-reviewed publications.

Eleven percent of respondents said that within two years, real-world data will be used for converge decision making. Just over nine percent said that real-world data will be used for drug efficacy and safety within two years, and the same percentage said real-world information will be used for clinical utility evidence development over the next two years.

Within three to five years, 12.4 percent of respondents believe that real-world data will be used for regulatory submissions, while just over ten percent think real-world data will inform claims adjudication or expansion of drug indications.

While precision medicine is becoming more mainstream, it is still a nascent discipline. Sharing the details of initiatives across the healthcare community will serve to accelerate adoption and determine future best practices so that we can truly harness precision medicine informatics for better outcomes, said Lle White, CEO, XIFIN.

For instance, the survey results demonstrate early adopters are already thinking about how high- quality real-world data will support and potentially accelerate clinical utility evidence development, coverage decision making, claims adjudication, expansion of drug indications, and regulatory submissions.

Powerful information like this is essential to reducing the cost of healthcare and improving patient outcomes, White added. It is imperative that organizations have a real-world data strategy both from a real-time access standpoint as well as from an actionable analytical insights perspective.

Precision medicine initiatives were also found to have a positive impact on certain quality metrics. Approximately 74 percent of respondents said precision medicine initiatives are increasing organizations ability to access real-world data. Almost 65 percent noted that precision medicine is improving organizations ability to query this data.

Additionally, 76.7 percent of healthcare professionals said precision medicine initiatives are having a positive impact on patient outcomes, while 53.3 percent said these initiatives are boosting patient satisfaction.

Over 76 percent said that precision medicine projects were helping care teams make better decisions, and 58.8 percent said precision medicine is increasing care teams ability to deliver personalized care. Nearly 56 percent said these initiatives are helping provide clinical decision support to care teams.

These findings indicate that with advanced technologies and comprehensive data, precision medicine could help health systems achieve their care goals. Going forward, if health systems adopt the right tools and develop effective solutions, precision medicine initiatives may become a larger part of the healthcare landscape, enabling organizations to deliver more informed, quality care.

Precision medicine and population health informatics offer the potential to infuse data at its most basic unit, the report concluded.

In addition, they put accompanying insights from aggregated de-identified data into precision medicine practitioners hands via the software that they use every day to support the decisions they need to make as part of the patient care journey.

Visit link:
Over 70% of Orgs Say Precision Medicine Meets or Tops Expectations - HealthITAnalytics.com

Read More...

10 Years Ago, DNA Tests Were The Future Of Medicine. Now Theyre A Social Network And A Data Privacy Mess. – BuzzFeed News

December 15th, 2019 7:44 am

Ariel Davis for BuzzFeed NewsShare on Facebook Share on Facebook Share on Pinterest Share on Pinterest Pinterest Pinterest

Genetics just got personal. So boasted the website of 23andMe in 2008, just after launching its DNA testing service.

As we entered this decade, a small cohort of companies 23andMe, its Silicon Valley neighbor Navigenics, and Icelandic competitor deCODE Genetics were selling a future of personalized medicine: Patients would hold the keys to longer and healthier lives by understanding the risks written into their DNA and working with their doctors to reduce them.

We all carry this information, and if we bring it together and democratize it, we could really change health care, 23andMe cofounder Anne Wojcicki told Time magazine when it dubbed the companys DNA test 2008s invention of the year, beating out Elon Musks Tesla Roadster.

But in reality, the 2010s would be when genetics got social. As the decade comes to a close, few of us have discussed our genes with our doctors, but millions of us have uploaded our DNA profiles to online databases to fill in the details of our family trees, explore our ethnic roots, and find people who share overlapping sequences of DNA.

Advertisement

Its become like Facebook for genes, driven by the same fundamental human desire to connect. And, as with Mark Zuckerbergs social media behemoth, this is the decade we reckoned with what it really means to hand over some of our most personal data in the process.

A 23andMe saliva collection kit for DNA testing.

It all panned out differently from the way I imagined in 2009, when I paid $985 to deCODE and $399 to 23andMe to put my DNA into the service of science journalism. (I spared my then-employer, New Scientist magazine, the $2,500 charge for the boutique service offered by Navigenics.)

I was intrigued by the potential of DNA testing for personalized medicine, but from the beginning, I was also concerned about privacy. I imagined a future in which people could steal our medical secrets by testing the DNA we leave lying around on discarded tissues and coffee cups. In 2009, a colleague and I showed that all it took to hack my genome in this way was a credit card, a private email account, a mailing address, and DNA testing companies willing to do business without asking questions.

Advertisement

Much of the rest of what I wrote about DNA testing back then reflected pushback from leading geneticists who argued that the companies visions of personalized medicine werent ready for primetime.

As I explored the reports offered by 23andMe and deCODE, I couldnt help but agree especially when deCODE wrongly concluded that I carry two copies of a variant of a gene that would give me a 40% lifetime chance of developing Alzheimers. (Luckily, it wasnt cause for panic. Id pored over my DNA in enough detail by then to know that I carry only one copy, giving me a still-elevated but much less scary lifetime risk of about 13%.)

Despite such glitches, it still seemed that medicine was where the payoffs of mainstream genetic testing were going to be. As costs to sequence the entire genome plummeted, I expected gene-testing firms to switch from using gene chips that scan hundreds of thousands of genetic markers to new sequencing technology that would allow them to record all 3 billion letters of our DNA.

So in 2012, eager to provide our readers with a preview of what was to come, New Scientist paid $999 for me to have my exome sequenced in a pilot project offered by 23andMe. This is the 1.5% of the genome that is read to make proteins and is where the variants that affect our health are most likely to lurk.

Experts at the Medical College of Wisconsin in Milwaukee analyzed my exome. While they werent at that point able to tell me much of medical significance that I didnt already know, the article I wrote from the experience in 2013 predicted a future in which doctors would routinely scour their patients genomes for potential health problems and prescribe drugs that have been specifically designed to correct the biochemical pathways concerned.

Advertisement

Im glad I included an important caveat: This may take several decades.

By then, the revolution promised by 23andMe and its competitors was faltering. Navigenics and deCODE had both been acquired by bigger companies and stopped selling DNA tests directly to the public.

23andMe, backed by the deep pockets of Google and other Silicon Valley investors, had enough cash to continue. But it fell foul of the FDA, which had decided that the company was selling medical devices that needed official approval to be put on the market. In a 2013 warning letter, the FDA said that 23andMe had failed to provide adequate evidence that its tests produced accurate results. By the end of 2013, 23andMe had stopped offering assessments of health risks to new customers.

Since then, the company has slowly clawed its way back into the business of health. In 2015, it was given FDA approval to tell customers whether they were carriers for a number of inherited diseases; in 2017, it started providing new customers with assessments of health risks once more.

I recently updated my 23andMe account, getting tested on the latest version of its chip. My results included reports on my genetic risk of experiencing 13 medical conditions. Back in 2013, there were more than 100 such reports, plus assessments of my likely responses to a couple dozen drugs.

In the lab, discovery has continued at a pace, but relatively few findings have found their way into the clinic.

Advertisement

If youve recently been pregnant, you were probably offered blood tests to tell whether your fetus had a serious genetic abnormality. And if youve been diagnosed with cancer, a biopsy may have been sequenced to look for mutations that make some drugs a good bet and other ones a bust. Neither would have been common a decade ago.

But the wider health care revolution envisaged by Wojcicki remains far off.

A few weeks ago, I saw my doctor to discuss my moderately high blood cholesterol and had a conversation that Id once predicted would be common by now. I had signed up for a project called MyGeneRank, which took my 23andMe data and calculated my genetic risk of experiencing coronary artery disease based on 57 genetic markers, identified in a 2015 study involving more than 180,000 people.

My genetic risk turns out to be fairly low. After I pulled out my phone and showed my doctor the app detailing my results, we decided to hold off on taking a statin for now, while I make an effort to improve my diet and exercise more. But it was clear from her reaction that patients dont usually show up wanting to talk about their DNA.

We have all these naysayers and an immense body of research that is not being used to help patients, said Eric Topol, director of the Scripps Research Translational Institute in La Jolla, California, which runs the MyGeneRank project.

Advertisement

Joseph James DeAngelo, the suspected "Golden State Killer," appears in court for his arraignment in Sacramento, April 27, 2018.

23andMes collision with the FDA wound up being a turning point in ways I didnt anticipate at the time. From the start, the company included an assessment of customers ancestries as part of the package. But after the FDA cracked down, it pivoted to make ancestry and finding genetic relatives its main focus. Offering the test at just $99, 23andMe went on a marketing blitz to expand its customer base competing with a new rival.

Ancestry.com launched its genome-scanning service in May 2012 and has since gone head-to-head with 23andMe through dueling TV ads and Black Friday discount deals.

DNA tests became an affordable stocking filler, as millions of customers were sold a journey of self-discovery and human connection. We were introduced to new genetic relatives. And we were told that the results might make us want to trade in our lederhosen for a kilt or connect us to distant African ancestors.

Today, Ancestrys database contains some 15 million DNA profiles; 23andMes more than 10 million. Family Tree DNA and MyHeritage, the two other main players, have about 3.5 million DNA profiles between them. And for the most dedicated family history enthusiasts, there is GEDmatch, where customers can upload DNA profiles from any of the main testing companies and look for potential relatives. It contains about 1.2 million DNA profiles.

Advertisement

So far, so much fun. But DNA testing can reveal uncomfortable truths, too. Families have been torn apart by the discovery that the man they call Dad is not the biological father of his children. Home DNA tests can also be used to show that a relative is a rapist or a killer.

That possibility burst into the public consciousness in April 2018, with the arrest of Joseph James DeAngelo, alleged to be the Golden State Killer responsible for at least 13 killings and more than 50 rapes in the 1970s and 1980s. DeAngelo was finally tracked down after DNA left at the scene of a 1980 double murder was matched to people in GEDmatch who were the killer's third or fourth cousins. Through months of painstaking work, investigators working with the genealogist Barbara Rae-Venter built family trees that converged on DeAngelo.

Genealogists had long realized that databases like GEDmatch could be used in this way, but had been wary of working with law enforcement fearing that DNA test customers would object to the idea of cops searching their DNA profiles and rummaging around in their family trees.

But the Golden State Killers crimes were so heinous that the anticipated backlash initially failed to materialize. Indeed, a May 2018 survey of more than 1,500 US adults found that 80% backed police using public genealogy databases to solve violent crimes.

Advertisement

I was very surprised with the Golden State Killer case how positive the reaction was across the board, CeCe Moore, a genealogist known for her appearances on TV, told BuzzFeed News a couple of months after DeAngelos arrest.

The new science of forensic genetic genealogy quickly became a burgeoning business, as a company in Virginia called Parabon NanoLabs, which already had access to more than 100 crime scene samples through its efforts to produce facial reconstructions from DNA, teamed up with Moore to work cold cases through genealogy.

Before long, Parabon and Moore were identifying suspected killers and rapists at the rate of about one a week. Intrigued, my editor and I decided to see how easy it would be to identify 10 BuzzFeed employees from their DNA profiles, mimicking Parabons methods. In the end, I found four through matches to their relatives DNA profiles and another two thanks to their distinctive ancestry. It was clear that genetic genealogy was already a powerful investigative tool and would only get more so as DNA databases continued to grow.

A backlash did come, however, after two developments revealed by BuzzFeed News in 2019. In January, Family Tree DNA disclosed that it had allowed the FBI to search its database for partial matches to crime-scene samples since the previous fall without telling its customers. I feel they have violated my trust, Leah Larkin, a genetic genealogist based in Livermore, California, told BuzzFeed News at the time.

Then, in May, BuzzFeed News reported that police in Centerville, Utah, had convinced Curtis Rogers, a retired Florida businessperson who cofounded GEDmatch, to breach the sites own terms and conditions, which were supposed to restrict law enforcement use to investigations of homicides or sexual assaults. That allowed Parabon to use matches in the database to identify the perpetrator of a violent assault.

Advertisement

Larkin and other genealogists condemned the move, calling it the start of a slippery slope that would see the method being used to investigate more trivial crimes.

As barbs flew between genealogists working with law enforcement and those who advocate for genetic privacy, GEDmatch responded with new terms of service that extended the definition of violent crime, but also required users to explicitly opt in for their DNA profiles to be included in law enforcement searches.

Overnight, GEDmatch became useless for criminal investigations. Since then, the number of users opting in for matching to crime-scene samples has slowly increased, and now stands at more than 200,000. But progress in cracking criminal cases has remained slow.

Now that cops have seen the power of forensic genetic genealogy, however, they dont want to let it go. In November, the New York Times revealed that a detective in Florida had obtained a warrant to search the entirety of GEDmatch, regardless of opt-ins. It seems only a matter of time before someone tries to serve a warrant to search the huge databases of 23andMe or Ancestry, which dont give cops access sparking legal battles that could go all the way to the Supreme Court.

Genetic privacy, barely mentioned as millions of us signed up to connect with family across the world and dig into our ancestral roots, is suddenly front and center.

This week, Rogers and the other cofounder of GEDmatch, John Olson, removed themselves from the heat when they sold GEDmatch to Verogen, a company in San Diego that makes equipment to sequence crime-scene DNA. Verogen CEO Brett Williams told BuzzFeed News that he sees a business opportunity in charging police for access to the database but promised to respect users privacy. Were not going to force people to opt in, he said.

Advertisement

But it isnt just whether cops can run searches against your DNA. 23andMe may not share your information with law enforcement, but customers are asked when they signed up whether if they are OK with their de-identified DNA being used for genetic research.

It might not be obvious when you fill in the consent form, but this lies at the heart of 23andMes business model. The reason the company pushed so hard to expand its database of DNA profiles is to use this data in research to develop new drugs, either by itself or by striking deals with pharmaceutical companies.

Ancestry has also asked its users to consent to participate in research, teaming up with partners that have included Calico, a Google spinoff researching ways to extend human lifespan.

You might be comfortable with all of this. You might not. You should definitely think about it because when the information is your own DNA, there really is no such thing as de-identified data.

That DNA profile is inextricably tied to your identity. It might be stripped of your name and decoupled from the credit card you used to pay for the test. But as 23andMe warns in its privacy policy: In the event of a data breach it is possible that your data could be associated with your identity, which could be used against your interests.

Advertisement

And because you share a large part of your genome with close relatives, when you put your DNA profile into a companys database, you arent only making a decision for yourself: Their privacy is on the line, too.

Whether its due to concerns about privacy, a saturated market, or just that the novelty has worn off, sales of DNA ancestry tests are slowing. Ancestry has responded by offering a new product focused on health risks. Unlike 23andMe, it requires that tests are ordered through PWNHealth, a national network of doctors and genetic counselors.

Will this be the development that takes us back to the future I once imagined? Maybe so, but if the roller coaster of the past decade has taught me anything, its to be wary about making any predictions about our genetic future.

Peter Aldhous is a Science Reporter for BuzzFeed News and is based in San Francisco.

Contact Peter Aldhous at peter.aldhous@buzzfeed.com.

Got a confidential tip? Submit it here.

Go here to read the rest:
10 Years Ago, DNA Tests Were The Future Of Medicine. Now Theyre A Social Network And A Data Privacy Mess. - BuzzFeed News

Read More...

Personalized CF Medicine to be Tested for Rare Genetic Defects in Europe – Cystic Fibrosis News Today

December 15th, 2019 7:44 am

Three investigative therapies by Proteostasis Therapeutics PTI-801, PTI-808, and PTI-428 showed potential to treat cystic fibrosis (CF) patients ineligible for approved CFTR modulators after patient-specific lab models produced promising results that support a future clinical trial.

Funded by the EUs initiative HIT-CF (Human Individualized Therapy of CF), this early study was conducted on patient organoids, which are miniaturized organ models derived from patient cells.

Based on the positive results, a clinical trial in adult CF patients is expected to start in 2020. If successful, the trial results may serve as the basis for a marketing authorization applicationin Europe in 2021.

With the help of CF-Europe (a patient organization) and the European Cystic Fibrosis Society Clinical Trial Network (ECFS-CTN), HIT-CF has been recruiting adult CF patients to collect tissue samples and create organoids, three-dimensional organ models grown in the lab.

Organoids mimic several characteristics of the organ from which they are derived, and are genetically identical to the donor. As such, they allow researchers to study biological processes and response to treatments in an environment that closely resembles human organs. As organoids are basically human cells cultured outside the body, they are said to be ex-vivo models.

The idea is to screen treatment candidates in the lab using intestinal organoids, or mini-intestines, obtained from rectal tissue (biopsies) of patients, which are collected through a quick and painless procedure. Then, based on how the organoids respond to each therapeutic candidate, a group of patients will be selected to enroll in a clinical trial.

Because the organoids can help determine the therapeutic candidate most likely to give the best results, researchers can personalize treatments for each patient before starting the trial.

So far, intestinal organoids from more than 300 patients have been created, of which 65 have been used to test Proteostasis potential CFTR modulators.

Proteostasis is honored to have been invited to participate in the HIT-CF project, and is the only company in the group with a combination of novel CFTR modulators being testedex-vivo. We are very enthusiastic about the progress of the study, Geoffrey Gilmartin, MD, chief medical officer of Proteostasis, said in a press release.

The positive results obtained on organoids support the launch of a clinical trial called CHOICES Crossover trial based on HumanOrganoidIndividual response inCF EfficacyStudy that will test the potential treatments on patients whose organoids responded favorably to the agents.

The study will also evaluate if organoids are good models to identify promising CF therapies, that is, if the responses measured on organoids translate to potential clinical benefits in patients, as reflected by lung function tests (FEV1) or sweat tests.

CHOICES will be a placebo-controlled, double-blind study that includes an eight-week treatment period, plus six months of constant dosing.

The study includes Proteostasis three candidate CFTR modulators, specially intended for patients who carry rarer CFTR genetic defects. All three compounds have different modes of action. PTI-801 works as a CFTR corrector, PTI-808 is a CFTR potentiator, and PTI-428 is a CFTR amplifier.

The trial is planned to start in mid-2020, with its first data anticipated for the end of 2020.

If moving forward, CHOICES will become the first trial based on personalized medicine for CF patients.

The inequality in access to CFTR modulators is an acute problem across Europe where 1 in 5 individuals do not have a F508del mutation [the most common CF-causing mutation]. In addition, drug reimbursement policies are leading to an ever-growing gap between patients who do, and those who do not have effective treatment options, said Christiane De Boeck, Work Package Leader at HIT-CF.

At HIT-CF Europe, we believe that novel strategies such as personalized medicine and development of new treatment options are central to addressing the inequality of access across the continent. We are thrilled with these initial results and look forward to providing additional updates, De Boeck added.

Gilmartin said that in Europe more than 2,300 adult CF patients are ineligible for approved CFTR modulators, and therefore excluded from participating in clinical trials.

This projects proposed personalized medicine approach is paving a potential new way to develop and provide access to novel CFTR modulators for patients with the most dire need for treatment options that target the cause of the disease. Additionally, based on an individual patients disease phenotype, and not just the genetic designation, this approach could also create a new path towards more effective treatment for all people with CF, Gilmartin said.

Proteostasis is also running a clinical trial evaluating a combination of the three candidate therapies for the treatment of CF patients who have at least one copy of the F508del mutation in the CFTR gene.

Ana is a molecular biologist enthusiastic about innovation and communication. In her role as a science writer she wishes to bring the advances in medical science and technology closer to the public, particularly to those most in need of them. Ana holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she focused her research on molecular biology, epigenetics and infectious diseases.

Total Posts: 336

Patrcia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.

Visit link:
Personalized CF Medicine to be Tested for Rare Genetic Defects in Europe - Cystic Fibrosis News Today

Read More...

Thanks to AI, medical treatments are becoming more personalized – The Next Web

December 15th, 2019 7:44 am

Artificial Intelligence has come a long way since it was in its blooming stages in the 1940s. It was a time when the direct interaction between AI and humans seemed impossible and people were even scared by the thought. All sorts of theories started emerging that made artificial intelligence look deadly for humans. The idea of robots or droids were thought of as something that could hurt the human population and even drive them to extinction. In spite of all theories, researchers were able to predict one thing for sure. Artificial intelligence will be able to transform lives and the way humans interact with one another. It will reshape the societies and industries that we know today.

Welcome to 2019, an era where artificial intelligence is vividly present all around us. In other words, we are living in the age of AI. Take a look around you. Be it the smart assistant on our mobile phones, websites, e-commerce platforms, search engine results, home automation appliances, classrooms, and more. Every single element is trying to adopt AI and cause an impact for the good. This is in turn radically transformssocieties and pushespeople to develop emotional bonding with their gadgets and AI devices. Today, when we want to find directions to a place, we do not stop by strangers and ask them. Instead, we turn on Google maps and let technology guide us.

One of the biggest breakthroughs in artificial intelligence has been its implementation in the healthcare sector. One of the most fundamental industries in the world, the healthcare sector is far behind in todays world. Even though technological marvels are constantly fascinating in the world, there is a significant amount of work that needs to be done in the healthcare sector. From diagnosis to medicine and providing healthcare facilities in rural areas, artificial intelligence has a lot of scope for health care support.

However, there has been some significant progress in the healthcare industry. All thanks to artificial intelligence that was powered by the wave of digitization. As more and more organizations are turning digital, its providing an abundance of data for machines to work upon them. Now we have robots that are successfully performing surgery on patients, software programs that are better diagnosing diseases far better than traditional pathological practices, and wearable devices that can monitor our health and send updates about alarming situations in real-time.

Still, theres an emerging need for transformation in the field of medicine. We still have drugs that address the concern of a mass population, only to leave a few with side effects. Similarly, diseases like cancer do not have any permanent remedy or targeted course of medication that treats the patient well without leaving them with any side effects. Similarly, people over the age of 50 are one of the fastest-growing demographic groups around the world. Its creating a lot of challenges for the global economy and the healthcare sector. These people need to be provided with efficient care and medical support that is targeted towards the longevity of their lives.

The Longevity Industry that provides healthcare support to the population above 50 is turning into a multi-trillion dollar industry, with close to 260 companies in the UK alone. Any progress in the longevity distribution at scale will have a huge impact and multiplicative effects on economies and societies around the world. After all, it would be a huge loss if the experienced population who have been responsible for more than a few innovations in the world are facing sudden deterioration in health in a way that reduces their quality of life. Not only will it be a huge loss to the economies but also result in increased dependency on the healthcare system. Having said this, artificial intelligence has a lot of potentials to manifest in this field and come up with solutions that target the emerging needs of the population accurately.

Research indicates that increasing the lifespan of humans even by one year will decrease the suffering of tens of millions of people and improve the quality of life for billions of others. One such effort in this direction is personalized medicine that targets the individual needs of humans with precision. So, lets say that if a person has asthma, precision medicine will only focus and target the cells that are responsible for asthma and help in regenerating them. This would leave other portions or tissues of the human body untouched and treat only what was needed. Therefore, in place of treating generalized symptoms, AI can help shift medicine towards prevention, personalization and ultimately precision.

With the advent of digitization in the healthcare sector, more and more patent records are going digital. This practice is helping researchers and medical experts understand the history of a patient in detail with the past treatments and health support theyve received. The vast amount of data collected from thousands of such medical records can be studied and used by AI to understand how a particular treatment can impact a particular gene inside the human. Moreover, digitization is also enabling researchers from all walks of life to work together, thus, laying an excellent foundation for biotechnology and computer experts to work together towards personalized medicine.

For example, CRISPR is a gene-editing technology that is being used to target the DNA sequences precisely. With this, medical experts can deliberately activate or inhibit certain genes in human beings. This demonstrates that there is a strong ability to target an individuals distinctive molecular and genetic profile, thus opening up new opportunities for personalized medicine.The National Institute of Health describes precision medicine as an emerging approach for the treatment of diseases and their prevention, which takes a persons gene variability, environment and lifestyle into account. It requires the assistance of deep learning algorithms that can learn from the data at an unprecedented rate and combine the knowledge of medical experts to reach a decision.

However, precision medicine will not be the end of human touch. It will still require vast expertise of medical experts to analyze the results obtained from machines and understand its real-world implications for the patient. With wearable devices, electronic health records and information about the geographic and demographic history of the patient, deep learning algorithms in AI have a lot of potential to device personalized medicine for people that target precision issues with high accuracy.

This article was originally published on Towards Data Science byJames Warner, a business intelligence analyst with knowledge on Hadoop/Big data analysis at NexSoftSys.com

Read next: Telegram exec should testify in UK over alleged illegal token sales, says US judge

See the original post:
Thanks to AI, medical treatments are becoming more personalized - The Next Web

Read More...

Pelosi drug bill passes … and it’s off to the Senate graveyard – Politico

December 15th, 2019 7:44 am

With help from Rachana Pradhan and Dan Goldberg

House Speaker Nancy Pelosis drug bill passes the House, but the Senates another matter.

President Donald Trumps FDA pick sails through the Senate and into the soup of vaping and other hot issues.

FDA encourages a focus on pediatric cancer with a shift to molecular targets.

A message from the Partnership for Americas Health Care Future:

New polling shows that lowering costs is the top health care priority for American voters, but embracing a one-size-fits-all new government health insurance system be it Medicare for All, Medicare buy-in, or the public option would mean higher taxes for middle-class families. Get the facts: Learn more.

Happy Friday and welcome back to Prescription Pulse! Were in the home stretch of 2019, just need to get a little thing called government funding done. Know what pharma and device provisions could make it in? Send pharma news, tips and fun reads to Sarah Owermohle (sowermohle@politico.com or @owermohle) and Sarah Karlin-Smith (skarlin-smith@politico.com or @sarahkarlin).

PELOSI DRUG BILL PASSES AND ITS OFF TO THE SENATE GRAVEYARD House Democrats overcame infighting within their ranks Thursday, passing a bill that for the first time would require the government to negotiate prices for costly drugs. The sweeping measure from Pelosi, H.R. 3 (116), hands Democrats a legislative victory to tout in the 2020 electionson a Trump administration priority, no less.

The measure passed 230-192, with two Republicans breaking ranks to support the measure. Eight Democrats jumped party lines to vote for a GOP amendment to replace the bill with H.R. 19 (116), a bundle of bipartisan provisions like measures banning pay-for-delay deals or capping seniors out-of-pocket costs, while avoiding controversial moves like negotiation or price hike caps.

In the Senate, Mitch McConnell has already said the bill is dead on arrival. But the majority leader hasnt committed to taking up his chambers alternative, a bipartisan measure from Senate Finance leaders Chuck Grassley (R-Iowa) and Ron Wyden (D-Ore.).

Grassley jumped on the House bill Thursday afternoon, saying it would result in dozens fewer therapies coming to market and that his bill was the only way forward. The House has acted and now the Senate must act, Grassley said.

Trump made vague promises to cut drug prices, including allowing government negotiations, during his 2016 campaign. But several promises have since faltered: courts killed a rule to require prices in drug ads, and the administration discarded a rule eliminating rebates over concerns it would increase premiums. The White House has thrown its support behind Grassleys bill, but the senator has been unable to rally the GOP votes.

Democrats aim to seize control of the drug pricing narrative in 2020. I believe we need real, substantive reforms, said Rep. Katie Porter (D-Calif.), a freshman who flipped her Orange County district last year, "and for a while, so did our president.

HAHN SAILS THROUGH SENATE FDA has a new leader. The Senate voted 72-18 Thursday to confirm the nomination of Washington newcomer Stephen Hahn.

Unlike his predecessor Scott Gottlieb who ultimately won much praise from Democrats who hadn't supported his nomination Hahn has no track record of working and profiting from the drug industry. He also lacks the prolific bibliography Gottlieb accumulated over the years writing on FDA-related policy, making it harder for Democrats to oppose him. Plus, Democrats were eager to see the departure of acting FDA chief Brett Giroir, the HHS assistant secretary of health, a conservative who has backed reproductive health policies opposed by the left.

But will his popularity last? Hahns bipartisan support will be tested by challenging political and public health issues, most notably how to regulate the booming e-cigarette industry amid an outbreak of serious lung illnesses associated with some vaping products.

The Trump administration promised a ban of flavored vaping products in September but in November retreated from that position after an outcry from free-market advocates and the vaping industry.

Hahn offered few hints throughout his confirmation process on how he would deal with vaping or other controversial topics like whether FDA should permit the importation of drugs from overseas to lower medication costs.

NEW REQUIREMENTS FOR PEDIATRIC ASSESSMENTS OF CANCER MEDS The agency issued draft guidance Thursday outlining how it will implement a provision in a 2017 law designed to ensure more cancer drugs are studied in children. Earlier laws requiring pediatric studies of drugs developed for adults only applied if children suffered from the same disease. But most adult cancers rarely occur in children, leading to gaps in pediatric cancer drug development.

Molecular targets a game changer: Researchers have found that a molecular-targeted drug that works to treat one cancer in adults may treat a different cancer in children if the same molecular target is relevant to both.

Sponsors of new cancer drugs for adults will now need to submit a report on pediatric cancer investigations for the drug with their marketing application to FDA, if the agency determines the target to be substantially relevant to a pediatric cancer. The requirements apply to drug applications submitted on Aug. 18, 2020 or later.

The guidance described how FDA will determine whether a molecular target is relevant and explains what should be in an initial pediatric study plan. FDA says studies described in the plan should evaluate dosing, safety and preliminary efficacy.

PHRMA SUES OVER OREGON DRUG PRICE LAWS The drug lobby on Monday challenged as unconstitutional two Oregon laws aimed at boosting transparency around prescription drug prices and increases, Portland Business Journals Elizabeth Hayes reports.

A measure passed last year, OR HB4005 (18R), requires manufacturers to submit a report to the Oregon Department of Consumer and Business Services when a drugs price rises over a threshold, explaining the hike and listing costs for making and selling the medicine. A newer provision, OR HB2658 (19R), mandates that drugmakers give 60 days notice on price increases.

A coalition of hospitals, insurers and health care advocates backed the first bill, but PhRMA said both measures were misguided and unconstitutional. The state should focus on capping out-of-pocket costs or give patients more of the negotiated savings on drugs, it said in a release.

Colorado issues report on strategies to lower drug costs Potential quick win policies that the state may pursue include price transparency related to drug price increases or PBM payments; requiring drug rebates to be passed through to employers and patients; and aligning the states importation policy with a potential expansion of federal regulations that the Trump administration is pursuing. Colorado Gov. Jared Polis has made health cost containment a priority and is one of a handful of states pushing the Trump administration to allow importation of prescription drugs from Canada.

SUPREME COURT REJECTS ARIZONAS CASE AGAINST SACKLERS Mark Brnovich, Arizonas AG, had taken the unusual step of asking the nations top court to hear his lawsuit, which accuses the Sacklers, the family behind Oxycontin-maker Purdue Pharma, of funneling $4 billion from the drug company while it faced huge liability for its role in the opioid crisis. Arizona is one of thousands of jurisdictions suing Purdue, which has declared bankruptcy. A bankruptcy judge put a hold on pending lawsuits but Brnovich decided to try his luck with the justices anyway.

RESEARCHERS CRITICIZE FINANCIAL DEPENDENCE ON INDUSTRY A group of researchers has demanded that medical research, education and practice become independent of commercial influences, Politico Europes Judith Mischke reports. The international researchers, clinicians, regulators and citizen advocates warned in a British journal that while everyone wants to ground healthcare decisions in "trustworthy evidence," there are still "widespread financial conflicts of interest across medical research, education, and practice.

In the United States, about 60 percent of medical research is industry funded, they noted. In some cases, "published outcomes of industry-sponsored studies tend to favor sponsors products, creating a 'sponsorship bias' in the evidence base that overplays benefits and underplays harms, the group writes.

They offer two solutions: Governments should pass laws requiring public disclosure of company ties, or regulators should bar public health organizations from receiving industry funding.

A message from the Partnership for Americas Health Care Future:

More than 180 million Americans rely on employer-provided coverage and new polling shows a majority of voters would rather build on whats working in our current health care system than replace it with a one-size-fits-all new government-controlled health insurance system.

Whether its called Medicare for All, Medicare buy-in or the public option, American families would face unaffordable costs and lower quality care under a one-size-fits-all system the exact opposite of what they want. See the results from the tracking poll here:Learn more.

PRESCRIPTION DRUG FACTORIES POLLUTING WATERWAYS Wastewater treatment plants are not typically equipped to remove pharmaceuticals from the waterflow, and drug cocktails have shown up in rivers across the U.S., reports Stat News Natasha Gilbert. In one area downstream of a Morgantown, W. Va., plant, an anti-seizure medication was measured at nearly 90 times the amount considered safe for wildlife. Stat and Type Investigations identified Mylan, Pfizer, Teva and three others as drugmakers dumping substantial levels of pharmaceuticals into the watershed.

CAR-T MANUFACTURING PROBLEMS PLAGUE NOVARTIS Novartis has had to give away some of its CAR-T cell therapy, Kymriah, because the personalized blood cancer treatment, made from a patients immune cells, havent met FDAs specifications, Biopharma Dive reports. In those cases the company delivered the treatment as if were an unapproved drug, through an expanded access protocol. In other cases, the company hasnt been able to use the product its made at all. Novartis presented real-world data this week that showed that even when the product didnt meet specifications it could attack cancer with no increased safety risk. Manufacturing is just one of the hurdles for commercializing the personalized medicine, which costs $475,000 for leukemia and $373,000 for lymphoma.

More:
Pelosi drug bill passes ... and it's off to the Senate graveyard - Politico

Read More...

Is Single-Cell Sequencing the Solution to Treating Aggressive Blood… – Labiotech.eu

December 15th, 2019 7:44 am

The landscape of precision medicine has changed dramatically over the years. The completion of the Human Genome Project in 2003 has greatly accelerated our understanding of individual genomes, leading to the idea of precision medicine: medical care tailored to the individual.

Since then, science has progressed greatly. Today, we are able to look beyond identifying mutations and instead gain a very comprehensive view of the molecular biology taking place in tumor cells. We nowunderstand that each person has a unique genetic and molecular setup, and each cell in the human body is different. Based on this knowledge, single-cell analysis tools are being developed to analyze the genetic, transcriptomic, proteomic, and epigenetic features of each cell.

As a relatively new suite of technologies, single-cell analysis can greatly improve precision medicine, a feat that is especially important in cancer biology. By providing deeper insights into each individuals disease, single-cell analysis can address many of the current challenges in precision medicine.

One area in which single-cell analysis is starting to make a difference is personalized cancer treatment. Tumors often contain very heterogeneous cell populations, which makes selecting treatments extremely challenging. Conventional diagnostic techniques often rely on the bulk analysis of cells. By taking the average of all cells in a sample, it is easy to miss a cell subpopulation that can become resistant to treatment and cause a relapse.

Now one company has taken it upon itself to improve precision medicine using single-cell analysis: Proteona. Among its first targets are blood cancers, such as multiple myeloma. As one of the most aggressive blood cancers, the treatment of multiple myeloma comes with a number of challenges.

Myeloma is a very difficult disease to treat because it constantly relapses, explains Chng Wee Joo, Senior Consultant and Head of Department of Haematology-Oncology at the National University Cancer Institute Singapore. The tumor cells are highly heterogeneous, and the immune microenvironment also plays an important role, creating additional complexity. Typically, patients are treated with multiple drugs at the same time, which triggers side effects and is extremely costly. There is definitely a need for better precision medicine here.

While the traditional bulk analysis of a tumor biopsy only provides information on the average of all cells present in a sample, single-cell analysis allows clinicians to analyze different tumor cell subpopulations, which might be resistant to a specific treatment and could cause a recurrence of the disease. In the case of multiple myeloma, single-cell proteogenomics can also be used to analyze the malignant plasma cells gene and protein expression and can be used to decide what treatments are plausible for the individual patient.

By adding protein expression analysis to single-cell sequencing, clinicians can gain valuable information on protein and gene expression as well as a better resolution between different cell types compared to analyzing gene expression alone. This is important for understanding patient cell heterogeneity.

For example, single-cell proteogenomics can provide a detailed analysis of the immune cells involved in a disease, can help clinicians understand possible resistance, and can be used for patient stratification in precision medicine trials.

There is a huge value in combining total mRNA profiling and proteomics in single-cell sequencing, says Andreas Schmidt, CEO of Proteona. While single-cell proteogenomics can be applied in various fields, what we find most interesting is the ability to gain a good snapshot of the immune cells as well as of tumor cells in the same sample. And that is valid for solid tumors as well as for liquid tumors. The information we are dealing with is already directly relevant for immuno-oncology, immunotherapy, and cell therapy. But despite the huge clinical value that we can already see on the horizon, there are no commercial solutions that can move single-cell sequencing into the clinic. And that is where we see the sweet spot.

Proteona has developed a suite of technologies called the Enhanced Single-Cell Analysis with Protein Expression (ESCAPETM) platform. ESCAPE uses DNA-barcoded antibodies to obtain protein and gene expression information from individual cells. Available as an in-house service or a kit, the ESCAPE platform has been used extensively for peripheral blood mononuclear cells (PBMC) profiling, whole tumor analysis, and cell therapy characterization.

One of the key challenges of single-cell analysis is the enormous amount of data generated. Even the sequencing of a single tumor results in hundreds of millions of data points that have to be analyzed and interpreted.

Combining datasets from different sources is also challenging. Cross-experimental comparison is often impeded by batch-to-batch differences. Moreover, single-cell analysis often results in the detection of previously unknown cell populations. Manual intervention is often needed for cell clustering and cell annotation, which demands specialist expertise, takes time and is susceptible to human error and bias.

Proteona definitely evolved from being a wet lab company with a bit of IT to a company that is equal parts bio and tech, says Schmidt. With single-cell proteogenomics you end up with thousands of mRNAs and potentially hundreds of proteins. If you were to gate them all by yourself and annotate that data, it would take a long time and it would create a lot of bias. We try to avoid this by using machine learning and automatic algorithms. One key point of our work is that we started with the wet lab and have a very deep understanding of the techniques and biology. At the end of the day, the biology is what informs us, not the algorithms.

In a partnership with AI Singapore, Proteona is further developing its computational workflows to support the knowledge-driven analysis of single-cell proteogenomics data to create unbiased data sets. The collaboration aims to further the development of artificial intelligence (AI) tools for single-cell multi-omics data analysis.

In Autumn 2019, Proteona issued an oncology challenge, co-sponsored by NovogeneAIT, in which it called for proposals from scientists and clinicians working on major clinical problems in oncology. Participants were asked to send in an abstract describing how they would use the ESCAPE platform with the chance to win $50.000 worth of single-cell analysis services from Proteona and NovogeneAIT.

The grant was awarded to Cesar Rodriguez Valdes from the Wake Forest School of Medicine in Winston-Salem, US. The proposal aims to tackle the issue of treatment selection for multiple myeloma.

By applying single-cell proteogenomics in their patient-derived 3D organoid models, the team will compare cell populations in response to multiple drugs, identifying the difference in protein and gene expression patterns. These studies will help to elucidate the mechanism of chemo-sensitivity, and potentially help to choose the suitable chemotherapy combination for each patient.

We are excited about combining Proteonas single-cell proteogenomic analysis with our patient-derived organoid screening platform, says Rodriguez Valdes. Our ambition is to develop a predictive, validated test that will facilitate clinical decision-making and improve the outcome of multiple myeloma treatment. This grant will help us to move closer to that goal.

One major challenge in multiple myeloma management is how to select the most suitable treatment strategy for each patient, given the wide range of available therapies, adds Hartmut Goldschmidt, Head of Hemato-oncology in Heidelberg. Currently, the decision of which drug to use and when depends largely on the clinicians experience. There is an urgent need for tools that help clinicians make evidence-based choices. That is where single-cell multi-omics can be extremely valuable.

Other awardees of Proteonas challenge include the runner-up, Sanjay de Mel (National University Cancer Institute, Singapore), and the finalists Nicholas Gascoigne (National University of Singapore, Singapore), Steve Bilodeau (Universit Laval, Canada), and Aaron Tan (National Cancer Centre Singapore, Singapore).

With the growing complexity of drug development and the advancement of cell therapies and gene editing techniques, the need for single-cell proteogenomics in research and the clinic is increasing. A key application of single-cell proteogenomics will be the quality control of cell therapies.

Furthermore, although there is already genomic monitoring in place for many clinical trials, oncology trials would greatly benefit from single-cell proteogenomics monitoring.

Besides blood cancers, we see multiple potential areas where single-cell multi-omics will make a clinical impact, Schmidt says. By providing in-depth data on cell heterogeneity and combining that with powerful analysis tools, we are in the best position to help clinicians to decipher complex cases, from cell therapy to solid tumors. We are only starting to harness the power of single-cell analysis.

Are you interested in learning more about single-cell proteogenomics? Check out Proteonas website for more information or get in touch with its team of experts at [emailprotected]!

Images via Shutterstock.com and Proteona

The rest is here:
Is Single-Cell Sequencing the Solution to Treating Aggressive Blood... - Labiotech.eu

Read More...

Myriad’s Polygenic Risk Score Personalizes Risk of Breast Cancer for Woman with a Genetic Mutation in Important Breast Cancer Genes – GlobeNewswire

December 15th, 2019 7:44 am

Graph 1

PRS Significantly Modifies Lifetime Breast Cancer Risk in Mutation Carriers

Myriad Genetics, Inc.

SALT LAKE CITY, Dec. 14, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that results of a new validation study of the companys polygenic risk score (PRS) for breast cancer were presented at the 2019 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Tx. The key finding is that the PRS significantly improves the precision and accuracy of breast cancer risk estimates for women of European ancestry who have pathogenic variants (PV) in high- and moderate-penetrance breast cancer genes.

Our goal is to help women understand their risk of breast cancer so that they can take steps to live longer, healthier lives. Women who have a family history of breast cancer should consider hereditary cancer testing with the myRisk Hereditary Cancer test, said Jerry Lanchbury, Ph.D., chief scientific officer of Myriad Genetics. In this landmark study, we demonstrated that for women who test positive for a mutation in one of the five most common breast cancer genes, there are additional genetic factors called single nucleotide polymorphisms (SNPs) that can further influence their lifetime risk of breast cancer.

A summary of the study follows below. Follow Myriad on Twitter via @myriadgenetics and keep up to date with SABCS meeting news and updates by using the #SACBS19 hashtag.

Myriad Poster Presentation Title: Polygenic Breast Cancer Risk Modification in Carriers of High and Intermediate Risk Gene Mutations.Presenter: Elisha Hughes, Ph.D.Date: Saturday, Dec. 14, 2019, 7:009:00 a.m. Location: Poster P6-08-07

This validation study evaluated the 86-SNP PRS as a breast cancer risk factor for women who carry PV in the BRCA1, BRCA2, CHEK2, ATM and PALB2 genes and for PV-free women. The analysis included data from 152,012 women of European ancestry who received a myRisk Hereditary Cancer test as part of their clinical hereditary cancer risk assessment. The results demonstrated that the 86-SNP PRS significantly modified the breast cancer risk for women with pathogenic mutations in the five tested breast cancer genes (p-value <10-4). For some women, the PRS significantly increased the gene-based risk of breast cancer, while in others the gene-based risk was reduced (see Graph 1). Importantly, the greatest PRS risk-modification was observed in carriers of CHEK2, ATM and PALB2 mutations with some women reaching the risk levels associated with BRCA1 and BRCA2 mutations.

To viewGraph 1: PRS Significantly Modifies Lifetime Breast Cancer Risk in Mutation Carriers, please visit the following link:https://www.globenewswire.com/NewsRoom/AttachmentNg/d56c93ca-e00f-452d-b051-6325a578454c

These findings mean that we have the potential to significantly improve the precision of hereditary cancer risk assessment for women who test positive for mutations in the high and intermediate risk breast cancer genes, said Elisha Hughes, Ph.D., lead investigator and director of Bioinformatics at Myriad Genetics. We are optimistic that this additional genetic information can help clinicians more accurately predict the risk of breast cancer and provide the best care for their patients in the future.

Next StepsThe company plans to publish these new data in a peer reviewed medical journal and make the PRS available for U.S. women of European ancestry who test positive for mutations in breast cancer genes. The PRS currently is available as part of myRisk Hereditary Cancer enhanced with riskScore for women of European ancestry who test negative for pathogenic mutations in the breast cancer genes. Specifically, the riskScore test combines the PRS with the Tyrer-Cuzick model to estimate a womans 5-year and lifetime risk for developing breast cancer. The company is committed to making myRisk Hereditary Cancer enhanced with riskScore available to all ethnicities and is developing the test for women of Hispanic and African-American ancestry who test negative. The company is currently conducting the largest ever PRS study in African Americans and will present the data at a future meeting.

Please visit Myriad at booth #113 to learn more about our portfolio of genetic tests for breast cancer. Follow Myriad on Twitter via @myriadgenetics and keep up to date with Symposium news by using the hashtag #SABCS19.

AboutriskScoreriskScore is a new clinically validated personalized medicine tool that enhances Myriads myRisk Hereditary Cancer test. riskScore helps to further predict a womens lifetime risk of developing breast cancer using clinical risk factors and genetic-markers throughout the genome. The test incorporates data from more than 80 single nucleotide polymorphisms identified through 20 years of genome wide association studies in breast cancer and was validated in our laboratory to predict breast cancer risk in women of European descent. This data is then combined with a best-in-class family and personal history algorithm, the Tyrer-Cuzick model, to provide every patient with individualized breast cancer risk.

About Myriad myRisk Hereditary CancerThe Myriad myRisk Hereditary Cancer test uses an extensive number of sophisticated technologies and proprietary algorithms to evaluate 35 clinically significant genes associated with eight hereditary cancer sites including: breast, colon, ovarian, endometrial, pancreatic, prostate and gastric cancers and melanoma.

About Myriad GeneticsMyriad Genetics Inc. is a leading precision medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on five critical success factors: building upon a solid hereditary cancer foundation, growing new product volume, expanding reimbursement coverage for new products, increasing RNA kit revenue internationally and improving profitability with Elevate 2020. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, EndoPredict, Vectra, GeneSight, riskScore, Prolaris, Foresight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor StatementThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to the Companys polygenic risk score and data being featured at the 2019 San Antonio Breast Cancer Symposium being held Dec. 10-14, 2019 in San Antonio, Tx.; the potential to significantly improve the precision of hereditary cancer risk assessment for women who test positive for mutations in the high and intermediate risk breast cancer genes; this additional genetic information helping clinicians more accurately predict the risk of breast cancer and provide the best care for their patients in the future; publishing these new data in a peer reviewed medical journal and making the PRS available for U.S. women of European ancestry who test positive for mutations in breast cancer genes; making myRisk Hereditary Cancer enhanced with riskScore available to all ethnicities and developing the test for women of Hispanic and African-American ancestry who test negative; conducting the largest ever PRS study in African Americans and presenting the data at a future meeting; and the Company's strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2019, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

More:
Myriad's Polygenic Risk Score Personalizes Risk of Breast Cancer for Woman with a Genetic Mutation in Important Breast Cancer Genes - GlobeNewswire

Read More...

Page 791«..1020..790791792793..800810..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick